# Going Digital: A Survey on Digitalization and Large Scale Data Analytics in Healthcare

Volker Tresp, J. Marc Overhage, Markus Bundschus, Shahrooz Rabizadeh, Peter A. Fasching, Shipeng Yu

Abstract—We provide an overview of the recent trends towards digitalization and large scale data analytics in healthcare. It is expected that these trends are instrumental in the dramatic changes in the way healthcare will be organized in the future. We discuss the recent political initiatives designed to shift care delivery processes from paper to electronic, with the goals of more effective treatments with better outcomes; cost pressure is a major driver of innovation. We describe newly developed networks of healthcare providers, research organizations and commercial vendors to jointly analyze data for the development of decision support systems. We address the trend towards continuous healthcare where health is monitored by wearable and stationary devices; a related development is that patients increasingly assume responsibility for their own health data. Finally we discuss recent initiatives towards a personalized medicine, based on advances in molecular medicine, data management, and data analytics.

# I. INTRODUCTION

Data have always been the basis for a scientific approach to healthcare: diagnostics are supported by physiological measurement, laboratory data and diagnostic imaging; the analysis of treatment efficiency and potential disease causes is based on clinical and epidemiological studies. Study design and data acquisition used to be the main challenges whereas data volume and data management were not. We expect that this will change rapidly as new sources of healthcare data become increasingly relevant. The newly generated data sets are high-dimensional and abundant; data volume is simply exploding. In the same sense as "digitalization" stands for the increasing digital presence of individuals, services, and "things" in general, the term "digital health" is associated with the wealth of health-related data becoming available in digital form [1]. The management and the analysis of these data with the goal of gaining insights and making insights actionable is sometimes referred to as Healthcare Big Data [2], [3], [4]. Whereas the term "Big Data" might quickly fall out off fashion, the underlying issues and technological challenges covered in this paper most likely will not.

Volker Tresp is with Siemens AG, Corporate Technology and the Ludwig Maximilian University of Munich, Germany.

Markus Bundschus is with Roche Diagnostics, Germany.

Peter A. Fasching is with the University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, Los Angeles, California, USA and the University Hospital Erlangen, Department of Gynecology and Obstetrics, Erlangen, Germany.

Shipeng Yu is with LinkedIn, Mountain View, California, USA.

Driving forces for the changes include a number of recent political initiatives designed to shift care delivery processes from paper to electronic, with the goals of more effective treatments with better outcomes; cost pressure is a major driver of innovation. One example is the Health Information Technology for Economic and Clinical Health Act (HITECH Act) in the U.S. The focus of the HITECH Act is the meaningful use of an interoperable electronic health record (EHR), enabling the exchange of information across institutions. The overriding goals are that each involved healthcare professional has complete patient information, that patients are treated by the best available institution for their problems, that medical research results can have more immediate impact, and that overall effectiveness is increased. In the context of these initiatives, large volumes of data will be collected and many improvements in healthcare will be based on the analysis of these data, with improved outcome at manageable cost as main goal. As a precondition to realizing the full potential, fundamental changes in the healthcare system might be required and data privacy, data ownership and data security issues must be resolved.

"Variety" and "volume" are the Big Data aspects most relevant to healthcare. Variety means that detailed information about an individual must be available to personalize recommendations and interventions. Examples of the latter two are lifestyle recommendations, alarms, reminders, preventive measures, screenings, referrals, and treatment recommendations. Key issues are, first, how detailed patient information can be acquired, managed and stored, second, how the "intelligence" comes into the system and, third, how recommendations should be optimally communicated to stake holders.

Volume is important to gain valid insights and actionable solutions from healthcare data: If data on many individuals are collected, one can perform statistical analysis, data mining and train machine learning algorithms.

The goal of this paper is to provide an overview of how digital health might affect the future of healthcare — and the expected changes are dramatic. The paper is written for the interested reader with limited prior exposure to healthcare issues. It contains six major sections —organized along the digitalization sources— which describe different digitalization and analytics trends in some detail.

In the next section we consider the digitalization process within the clinic. As mentioned, many advances in clinical data management are based on a broader adoption of the EHR, which is the main driver for a digitalization of the clinical information systems. The introduction of a high quality EHR can lead to an improvement in patient safety and can increase transparency and accountability. It documents relevant clinical patient information and its data are the basis for many forms

J. Marc Overhage is with Cerner Corporation, Kansas City, Missouri, USA. Shahrooz Rabizadeh is with NantOmics, LLC and at NantBioScience, Inc, Culver City, CA, USA.

of analysis and decision support. Implementing EHRs faces challenges, mostly associated with the additional efforts and costs and the fear that the center of attention might move away from the patient to the IT system. We also discuss the current clinical data situation: what type of data typically are available and how they are documented and organized. We discuss the importance of shared terminologies, data security and data privacy.

Clinics increasingly collaborate in digitalization and Big Data projects with university institutes with analytics competencies and with commercial vendors. In Section III we describe a few specific projects. We also discuss some of the statistical issues that arise in integrating observed data from different sources, e.g., various biases, hidden confounders and batch effects.

Payers, registries and national health systems, as the U.K.'s NHS, have long collected healthcare related data across clinics. A novel development in recent years is that clinics are increasingly required to report data for purposes like quality control and policy development. Also, a lot can be gained if data can be exchanged between different care venues, as for example in integrated care. Health information exchange (HIE) encompasses all activities towards a mobilization of digital healthcare information across organizations within a region, community or hospital system [5]. We discuss the U.S. HIPAA regulations and the danger of data de-identification. The externalization of clinical data is covered in Section IV.

Healthcare increasingly becomes patient-centered and patients want to get in charge of their own health and their own health data. Families want to keep health profiles and make them accessible to authorized caregivers, like their family doctors. These trends are supported by a number of evolving cloud-based offerings. One can envision new IT platforms as basis for a revolution in healthcare management, supporting both a patient centric and a data centric view. Also, there are patients with one or several serious, sometimes chronic diseases who want to interact with a social community of patients with similar problems. Social media used by these patients may provide insights into drug effectiveness, adverse drug effects and can be useful for the detection and the tracking of infectious diseases. Patients are sometimes willing to make their data available for research and other uses via platforms like PatientsLikeMe. We discuss these developments in Section V.

Another big digitalization trend is increasing data capture during the course of everyday activities. Smart phones can collect fitness and health related data via a variety of sensors. These data can be analyzed by patients via platforms and apps and they can be communicated to healthcare providers. Over a patient's lifetime large amounts of personal data are collected and data analytics is offered as a service by platform operators. This mobile health (mHealth) supports efforts to "shift care to the left", i.e., to identify risk and intervene before disease develops; there is an increasing emphasis on prevention, rather then diagnosis and treatment. In addition to wearable devices, ambient sensors will play a role, in particular for the care of the elderly. These developments are discussed in Section VI.

Finally, there is a growing trend towards personalization in healthcare (i.e., more precise and personalized care) partially but not solely driven by the lower cost and increasing availability of molecular data in form of genomic (including the whole genome), proteomic and metabolic profiles. Treatment decisions are more and more based on molecular patient profiles; as a drawback, personalization comes at an increased level of complexity that easily overwhelms the decision maker. Large-scale analytics is essential for the generation of personalized decision rules derived from large sets of data, in line with the trend towards an evidence-based medicine. These are the topics of Section VII.

Section VIII summarizes the developments with an attempt of an evaluation and a discussion of opportunities and challenges. In this paper we focus primarily on the situation in the U.S. The main reason is that the U.S. is ahead in digitalization and large scale data analytics in general, and in healthcare in particular. Another reason is that the U.S. has the largest healthcare market worldwide. We will highlight the situation in other countries when relevant; in particular some of the developments in the U.K. are highly innovative and demonstrate emerging opportunities in a national healthcare system.

#### II. DIGITIZING HEALTHCARE DATA

#### A. Motivation

Healthcare is a large and complex enterprise that is relevant to every person on the planet. The digitization of healthcare data in a manner that is easy for computers to utilize is important to support the delivery of care through data visualization, collaboration and clinical decision support. Recently, the concept of a "learning healthcare system" has been introduced [6]. In a learning healthcare system data harvested from the care process is continuously analyzed and used to create insights into how the care delivery process should evolve.

When data are digitized, it is possible to create new and useful ways for visualization and analysis, with the potential to provide better insights into a patient's status and, optimistically, better decisions [7]. Another important application for digitized healthcare data is digitally supported clinical decision support (CDS). CDS systems combine the data with clinical knowledge to provide patient specific suggestions at the appropriate time in the care process. These systems have been demonstrated to improve the quality, safety and efficiency of care, though these advantages have not been universally observed [8], [9]. Lack of complete, timely and correct data frequently underlies the failure to achieve these benefits.

Complete information from *many patients* is the basis for analytics, i.e., statistical analysis, data mining and machine learning. A few authors have attempted to characterize the ways that healthcare systems hope to take advantage of analytics. Bresnick and colleagues considered the following items [10]:

- Identifying at-risk patients
- Tracking clinical outcomes
- Performance measurement and management
- Clinical decision making at the point of care
- Length of stay prediction
- Hospital readmission prediction

The goal of the latter is to avoid costly penalties for hospital readmissions, which were introduced by Medicare under the 2010 Patient Protection and Affordable Care Act (ACA).

Insurance companies have started to use data analytics to identify likely patients for hospital readmissions, which resulted in a 40-50% reduction for patients with congestive heart failure [11], [10].

Another study identifies the following uses for analytics [12]:

- Analytics-based drug discovery processes; study of drug efficacy; detection of adverse drug effects and drug-drug interactions
- Identification of better and safer therapies
- Optimal clinical trial designs and patient recruitment
- Evidence-based medicine to integrate clinical expertise and research results to support best care decisions
- Protocol-based medicine that draws on research results to identify best practices for specific conditions, medical histories and patient populations
- Personalized medicine that blends diverse data sources, including genetic profiles, with historical clinical data

These are mixes of descriptive tasks, prediction tasks and prescriptive tasks [10].

Descriptive analytics is a classical data mining task and extracts human understandable information from data in form of simple rules (association rule mining) or in visual form (visual analytics) [13]. Often the results are presented as a report. Typical projects might be to identify areas for improvement on clinical quality measures or on specific aspects of care. It is important to note that the human is in the loop and draws conclusions based on the findings [10].

For predictive analytics, traditional statistical methods or machine learning can be used. The task might be to forecast future procedures, diagnoses, or outcomes. Other tasks are patient condition monitoring with different alarm functions. The application of predictive models at the point of care requires a robust and high-quality infrastructure, which enables real-time data processing. "Medical devices must be fully integrated to provide up-to-the-second information on patient vitals to improve safety, while alerts and alarms have to be developed and presented to clinicians without hopelessly disrupting their workflows or annoying them into ignoring critical warning" [10]. The good news is that confounding factors, as long as their statistical properties are stationary, can be ignored in pure prediction problems; on the other hand, a predictive model trained in one clinic might not work well in another clinic, e.g., due to different patient profiles.

Prescriptive analytics encompasses the ability to recommend actions and to answer "what if" type of questions. Whereas a predictive model might recommend an action that is "typically" performed for a patient with particular properties, a prescriptive analysis would be able to prescribe an action that would lead to best predicted outcome. "Prescriptive analytics doesn't just predict what's likely to happen, but actively suggests how organizations can best take action to avoid or mitigate a negative circumstance" [10]. The requirements on data quality and system robustness are even greater. In particular, a prescriptive analysis requires a careful analysis and consideration of hidden confounders. Prescriptive analytics has been called "the future of healthcare Big Data ... the healthcare industry has an enormous opportunity by taking advantage of these decision-making abilities" [10].

# B. The Electronic Health Record

For decades, much of what was documented about a patient was in paper format and collected in a folder that was physically moved across the clinical departments and was eventually filed. Today, patient data are increasingly recorded and stored in an electronic form, the electronic health record (EHR) [14]. The EHR greatly improves the quality of the data documented and supports improvements in patient care by enabling analysis and decision support. In its most basic form, an EHR consists of the same paper documents except that they are scanned and stored digitally. Of course this does little to support analysis or clinical decision making. More advanced systems contain machine readable structured tables and digital reports, where ideally the latter are machine readable and semantically annotated. In these advanced systems, data are easily accessible to algorithms and analytic tools.

As we will discuss in Section IV, the HITECH Act has stimulated increased use of the EHR in both hospitals and ambulatory practices across the U.S. [15], [16], [17]. Meaningful use, as defined by HITECH, requires both the capability and actual use of the EHR to perform functions such as electronic prescribing and ordering of tests, electronic access to test results, medication alerts, and tracking of lab tests. In addition medical guideline support must be implemented. In some countries, the EHR is standard (e.g., in the Netherlands, New Zealand, Norway, Sweden and the U.K.), whereas countries like the U.S. and Germany are lagging behind. Surveys found that, despite much broader adoption over the last several years, U.S. physician enthusiasm for EHRs has not improved in the last 5 years [18]. The authors attribute the physician's lack of enthusiasm to doctors not seeing enough benefit from the EHR and that EHR products do not deliver all necessary functionalities, being difficult to use, and not being interoperable with each other. In addition, there are worries about data leakage, which is increasing in frequency [19], and compliance with regulations.

# C. Structured Data Capture

EHRs can only achieve their full potential if time and cost associated with data capture can be kept under control. While a good deal of clinical data can be obtained from other venues such as laboratory or radiology systems or from devices (e.g. vital signs, ventilators), a significant amount of data must be entered by providers. Because of the time and effort required for providers to capture structured data, they often question if there is sufficient value to warrant the negative impact on productivity [20], [21]. Contemporary EHRs are estimated to require an additional 48 minutes per day, much of which is devoted to documentation [22], [23].

Healthcare is complex, which is also reflected in the data: There are hundreds of thousands of clinical concepts that have to be represented. In order to accommodate this scale and simplify representations, coding systems have been adopted for clinical concepts. The concept of heart failure for example can be represented in the International Classification of Disease Version 9 Clinical Modification as "428.0". Unfortunately, there are multiple coding systems for most clinical concepts, so heart failure can also be represented by I50 (ICD-10), 16209

(DiseaseDB), D00633 (MESH), 42343007 (SNOMED) and others. Even more unfortunately, a good deal of data are coded using idiosyncratic clinical codes that are unique to a specific healthcare delivery system. This variation means that using the data often requires mapping or translation between coding systems which usually requires substantial human effort and, in some cases, a specific data model.

In addition to direct entry by providers or their surrogates, structured data can be derived directly from unstructured data including free text, images and other signals.

Radiology involves the acquisition, analysis, storage and handling of radiological images and certainly involves huge amounts of data, in particular when the analysis involves time, as in angiography, or all three spatial dimensions, as in whole body screening. Pathology involves the analysis of tissue, cell, and body fluid samples, typically via microscopic imaging. As pathology is digitized, increasing amounts of digital data are generated and need to be handled and stored. The standard is that medical specialists interpret the radiological and pathological images and describe the findings in written freetext or unstructured reports, although there is a trend towards template-based semi-structured reporting.

The computerized analysis of radiological and pathological images is an established research area involving sophisticated algorithms and is becoming increasingly clinically relevant [24], [25], [26]. The analysis typically involves some form of machine learning and the emerging field of deep learning has increasing impact [27]. Analysis generates qualitative and quantitative labels or tabs, which can be used in integrated analytics studies [28].

Written text is a major medium: The exact numbers vary, but a significant proportion of the clinically relevant information is only documented in textual format. Besides radiological and pathological reports, medically relevant textual sources are reports from other departments, notes, referral letters and discharge letters. Both researchers and commercial developers have devoted considerable effort to improve the efficiency of structured data capture from text and some hope that Natural Language Processing (NLP) will obviate the need for structured data capture; but advances have been incremental; while there is progress in focused areas, information extraction from clinical texts is notoriously difficult. Some of the reasons are that reports are ungrammatical, contain short phrases, non-standardized and overloaded abbreviations and employ an abundant use of negations and lists. Structured reporting, where the text is generated automatically and the physician simply enters keywords and short pieces of text, would be a great advance, but is currently not the standard [29], in part because it is typically more time consuming for the provider.

Another issue is that the structured data entered by providers or extracted from text need to be represented such that they can be "understood" by a computer, in other words healthcare systems need to be able to communicate effectively and in the same formalized language. Some languages are essentially simple taxonomies and vocabularies and are the basis for standards used in the billing process, such as ICD for diagnosis, CPT©for procedures, and SNOMED codes for diseases or conditions. For medications, there is the National Library of

Medicine's RxNorm, the National Drug Code (NDC) and others. Logical Observation Identifiers Names and Codes (LOINC©) define universal standards for identifying medical laboratory and clinical observations.

For billing purposes all involved players are highly motivated to employ the codes with great discipline. Implied statements in general take on simple forms, like "Patient X has Disease Y".

This changes if one wants to express some detailed medical finding accurately. Consider the phrases "43 yo female with history of GERD woke up w/ SOB and LUE discomfort 1 day PTA. She presented to [\*\*Hospital2 72\*\*] where she was ruled out for MI by enzymes. She underwent stress test the following day at [\*\*Hospital2 72\*\*]. She developed SOB and shoulder pain during the test." In order to utilize the information represented in this text, an application would first need to map and code the entities in the phrases and then formulate statements relating the complex sequential observations with many subtle phrases only understandable by trained experts. These challenges goes far beyond the expressiveness of currently used medical formal languages.

Genomic, proteomic and other molecular data (discussed more fully in Section VII), which are almost by their nature digital, will add an extensive amount and variety of structured data though, in current practice, an extremely limited subset derived from the molecular data will be all that is necessary for a particular application.

#### D. Data Silos

Other barriers to utilizing clinical data are the ubiquitous clinical data silos. In addition to the fragmentation of a patient's data across various participants in the healthcare ecosystem, each medical department historically has used its own department-specific database and reporting system, and only a portion of that information has typically been integrated into the EHR [30]. As an example, before a provider sees a laboratory test result displayed in their EHR, the data have traveled along a complex and convoluted path to get there: Laboratory instruments themselves are sophisticated computing and data management systems that pass data through laboratory instrument management systems and potentially laboratory information systems, through an interface engine and eventually to the EHR. Each phase supports specific data management and monitoring tasks and adds and loses pieces of data [31]. Another issue is that each data silo might code information differently, and building wrappers for the purpose of data integration is anything but simple. These challenges are the basis for the recent preference for integrated EHR platforms to share a common database across many departments, which largely eliminate the data silos inside an organization. In fact healthcare organizations have often accepted lesser functionality in order to achieve this benefit.

#### E. Clinical Data Integration Efforts

Some providers may have implemented a separate research data system such as i2b2 [32] or tranSMART [33]. These systems extract clinically relevant information from the EHR

and from other clinical resources and databases and integrate them into the research database. A research database can be a great resource for data analytics projects. Unfortunately installing a research database can be extremely demanding since it needs to access data from the data silos of the different departments. As discussed these databases might all have different structures and use different terminologies.

In contrast to clinical data, billing data —in part because of its simplicity and in part out of necessity— are consistently structured and are often part of a research database. Unfortunately, billing data does not contain much of the clinically relevant information and may not accurately and fully reflect clinical reality. Reasons are that providers may not be as careful in recording administrative data believing that it is not critical to be exactly correct or, in some cases, billing data may be coded to maximize reimbursement rather than to most accurately reflect the patient's clinical status.

Another important issue is that the temporal order of events is often not well documented in the data. To analyze the causal effects of a decision and to optimize decisions, it is important to know which information was available to the decision maker at the time of decision. At the current status of documentation, reconstructing the temporal order of events can be difficult.

# F. Privacy Protection and De-identification

De-identification is the process used to prevent a person's identity from being connected with information. Common uses of de-identification include human subject research, which requires privacy protection for research participants. Common strategies for de-identifying data sets are deleting or masking personal identifiers, such as name and Social Security Number, and suppressing or generalizing quasi-identifiers, such as date of birth and ZIP code. More sophisticated approaches use k-anonymity, l-diversity, epsilon differential privacy, differential identifiability coarsening, imputation, and data swapping [34]. Unfortunately, information can be lost in de-identification, making the data potentially less useful for analysis.

De-identification is difficult for clinical data in general but particular difficult for textual data since a personal identifier might appear unexpectedly in the middle of a text and also for genomic data, considering that a person's genetic profile is unique.

Appropriate patient consent may reduce the need for deidentification [35].

# III. MOBILIZING DATA IN A TRUSTED NETWORK

Integrated care is a worldwide trend in healthcare with the goal of achieving a more coordinated and integrated form of care provision. It may be seen as a response to the problems associated with the fragmented delivery of health in many countries. Integrated care —as some other forms of alliances and inter-clinical collaborations— permits the integration and evaluation of data from several sources. It supports analytics projects since the patient sample size simply is larger if compared to a single clinic, and since patients may stay for more problems within an integrated care system and for a longer time

span, possibly all their life; thus data on a particular individual are typically more complete.

In this section we describe representative projects where clinic networks team up with research centers —which provide expertise in data analytics, machine learning, and medical informatics— to explore the potential of clinical data analytics. The long-term vision behind these and similar projects is a system where patient data are analyzed online, and research insights rapidly becomes common practice, resulting in best care for each patient.

#### A. The Pittsburgh Health Data Alliance

The Pittsburgh Health Data Alliance is a collaborative Big Data effort involving Carnegie Mellon University (CMU), the University of Pittsburgh (Pitt) and the University of Pittsburgh Medical Center (UPMC). It is financed by the latter but all three institutions contribute grant funding [36].

The stated goals are characteristic for these types of projects: Primarily the consortium seeks to analyze and make use of the massive amounts of data generated in the healthcare system, including EHR patient information, diagnostic imaging, prescriptions, genomic profiles, insurance records, and data from wearable devices. The work will support the development of evidence-based medicine, and lead to the augmentation of disease-centered models with patient-centered models of care. The vision is a data-driven medicine based on a large sample of patients, which will assess an individual's disease risk and make personalized recommendations for treatments. Other intended outcomes are spinoff companies and promotion of economic development in the region [37].

The CMU plans to develop an automated patient diagnosis system. Based on automatically retrieved symptoms and lab findings the system searches medical literature and analyzes patient data to provide possible diagnoses. To refine the diagnosis additional tests might be requested.

The role of Pitt's Center for Commercial Applications of Healthcare Data (CCA) is to develop new technology for potential use in commercial theranostics, combining diagnostics with therapy and imaging systems. UPMC Enterprises leads the efforts to transfer the results to for-profit startup companies. A concrete collaboration topic concerns the early detection of disease outbreaks by tracking of over-the-counter medication sales. Involved are the "Real-Time Outbreak of Disease Surveillance" (RODS) Laboratory at Pitt and the "Event and Pattern Detection" (EPD) Lab at CMU's Heinz College.

Being one of the first sizeable Big Data projects in healthcare, the effort attracted the interest of a number of IT companies, which are supplying high-performance database platforms, business intelligence solutions, and platforms for integrating patient records. In general, there is an increasing care provider demand for Big Data functionalities in clinical information systems and vendors are adapting to these needs. In fact, considering the dramatic changes expected in healthcare, in which IT is expected to play a major role, many IT vendors are actively exploring future business opportunities.

# B. The Mayo Project

A collaborative effort between the Mayo Clinic and several departments at the University of Illinois is part of a large federal grant for the support of medical Big Data research [38]. The collaborative effort involves the Institute for Genomic Biology, the Department of Computer Science, the Coordinated Science Laboratory, the College of Engineering and the National Center for Supercomputing Applications (NCSA). The effort includes the setup of a new Center of Excellence for Big Data Computing and a network to move and share the data between researchers. The Campus Advanced Research Network Environment (CARNE) has been created with the goal of providing unrestricted high-speed access to off-campus locations for specific research purposes. A major project is the Knowledge Engine for Genomics, or *KnowEnG*<sup>1</sup>.

# C. Neonatal Intensive Care at Kaiser Permanente

This is an early project that demonstrated the potential of Big Data in intensive care. In current medical practice, newborns are typically taken to the neonatal intensive care unit (NICU) if the mother's temperature rises above a threshold because this may signal an increased risk of neonatal sepsis, a bacterial blood infection [39]. Kaiser Permanente has used data analytics to develop the interactive and online "Newborn Sepsis Calculator" that determines the probability of neonatal sepsis, allowing the care team to better determine which babies to evaluate and treat for infection [40].

#### D. Indiana Network for Patient Care

The Regenstrief Institute was an early advocate for clinical data interoperability based on information standards and leveraged that work to enable health information exchange both regionally and nationally. Regenstrief investigators implemented the Indianapolis Network for Patient Care (INPC) in 1995 with the goal of providing clinicians with data necessary for patient diagnosis and treatment at the point of care. In 2016, over 100 hospitals, thousands of physician practices, ambulance services, large local and the state public health departments, regional laboratories and imaging centers, and payers participate in the INPC. The federated data repository stores more than 4.7 billion records, including over 118 million text reports from almost 15 million unique patients. The data are stored in a standard format, with standardized demographic codes; laboratory test results are mapped to a set of common test codes with standard units of measure; medications, diagnoses, imaging studies, report types are also mapped to standard terminologies. The flows of data, which enable the INPC, support results delivery, public health surveillance, results retrieval, quality improvement, research and other services. Building on this experience, Regenstrief investigators have informed the development of the nationwide health information network program now called the eHealth Exchange ("Exchange").

The INPC data have been utilized by Regenstrief for many Big Data studies and projects including:

- The OMOP (Observational Medical Outcomes Partnership) [41] and the subsequent OHDSI (Observational Health Data Science and Informatics) [42] projects to utilize large scale observational data for drug safety studies
- The two projects were a basis for ConvergeHEALTH, an effort spearheaded by Deloitte that aims to offer comprehensive data sharing among key organizations. Deloitte has an analytics platform that allows hospital systems to compare results with tools designed to study certain patient outcomes: their OutcomesMiner tool helps users explore real-world outcomes for sub-populations of interest
- The Merck-Regenstrief Institute "Big Data" Partnership Academic-Industry Collaboration to Support Personalized Medicine was formed in 2012 to leverage the INPC to support a range of research studies that use clinical data to inform personalized healthcare. The partnership has funded 50 projects to date. Industry commentators have observed that such partnerships between industry and academia, and between and among other payers, are essential as neither sector alone can undertake such projects
- The Indiana Health Information, a non-profit organization created to sustain the INPC's operations, entered into a partnership agreement with a commercial predictive analytics company, Predixion, to develop new predictive applications aimed at further supporting the patient and business needs of ACOs and hospitals. The INPC database supports Predixion's current and future solution development

# E. Clinical Data Intelligence

Clinical Data Intelligence ("Klinische Datenintelligenz") is a German project funded by the Federal Ministry for Economic Affairs and Energy (BMWi) and involves two integrated care providers, i.e., the University Hospital Erlangen and the Charité Berlin, two globally acting companies, i.e., Siemens AG and the Siemens Healthineers, and application and research centers from the University of Erlangen, the German Research Centre for Artificial Intelligence (DFKI), Fraunhofer, and Averbis [28], [43].

The project puts particular emphasis on terminologies and ontologies, on metadata extraction from textual sources and radiological images and on the integration of medical guidelines as a form of prior knowledge. As part of the project a central research database is installed which serves all research and application subprojects. The project also addresses business models and clinical app infrastructures suitable for large-scale data analytics.

The core functionalities are realized by an integrated learning and decision system (ILDS). The ILDS accesses all patient specific data and provides analytics, predictive and prescriptive functionalities. The ILDS models and analyzes clinical decision processes by learning from the EHR's structured data such as diagnosis, procedures, and lab results. The ILDS also analyzes medical history, radiology, and pathology reports and includes

<sup>1</sup>http://www.knoweng.org/

guideline information. In addition, the ILDS considers genomic data, and molecular data in general, to explore the application of personalized medicine to clinical practice.

The ILDS will immediately be able to make predictions about common practice of the form: "For a patient with properties and problems X, procedure Y is typically done (in your clinic system)". More difficult, since it involves a careful analysis of confounders, is a prescription of the form: "For a patient with with properties and problems X, procedure Y is typically done (in your clinic system) but procedure Z will probably result in a better outcome".

An important outcome of the project will be a set of requirements for a future clinical documentation that will enable more powerful data analytics in the future. For example, patient complaints, symptoms, and clinical outcome are not always well documented. Readmission within a certain period of time (typically a month) is sometimes taken for a negative outcome. Alternatively one might define a hospital stay of more than a certain number of days as a negative outcome, where the threshold is specific to the Diagnosis Related Group (DRG). In some cases, for example after a kidney transplantation or mastectomy, the patient is closely observed, and outcome information is available, possibly over patient lifetime.

The ILDS partially uses deep learning (more specifically recurrent neural networks) to model the sequential decision processes in clinics [44].<sup>2</sup>

The project addresses two use cases in detail.

The first concerns nephrology. Kidney diseases cause a significant financial burden for the healthcare system. The aim of this work is to systematically investigate drug-drug interaction (DDI) and adverse drug reactions (ADR) in patients after renal transplantation and to realize an integrated decision support system. The use case is particularly interesting since longitudinal data covering several decades are available and since outcome information is available.

First ILDS results are reported in [44], [46].

The second use case concerns breast cancer, the most common malignancy in women. Relevant events are screening, diagnosis, therapy and follow-up care. Of special interest here is the determination of risk factors, the evaluation of the therapy and the prediction of side effects.

# F. Related Initiatives and Projects

In the U.S. and in other countries many similar initiatives have been started or are in preparation phase.

The Dartmouth Institute, Dartmouth-Hitchcock, Denver Health, Intermountain Healthcare, and the Mayo Clinic are the founding members of the "High Value Healthcare Collaborative (HVHC)", which is a collective of close to 100,000 physicians and close to 10 million patients across the U.S. In an early project, HVHC found strikingly different costs and processes for total knee replacements among four hospital sites, with one site performing significantly better than the others [47]. Subsequently, this site's best practices were shared with the other three and all four could reduce their lengths of stay for knee-replacement procedures by a full day [48].

The University of Michigan has announced a large Big Data Science Initiative targeting health issues in the context of mobility and wearable devices [49].

The University of Washington Tacoma has developed the "RiskO-Meter" using data analytics. It provides a risk score to clinicians and patients to predict the return of congestive heart failure patients to the hospital within the critical 30 day readmissions window [50].

Penn Medicine, part of the University of Pennsylvania Health System, is working on a Big Data project to develop predictive analytics to diagnose deadly illnesses. The backbone is a homegrown enterprise data warehouse, called *Penn Data Store*. An example is the prediction of the danger of severe sepsis, which relies on an analysis of six vital sign measurements and lab values. The model takes into account more than 200 clinical variables and enables Penn Medicine to detect 80 percent of severe sepsis cases as much as 30 hours before onset of septic shock (as opposed to just two hours prior, using traditional identification methods) [51].

#### G. Comments on the Value of Big Data Studies

Often the goal of Big Data studies is to draw causal conclusions, e.g., on the effectiveness of a drug or on a possible disease cause, and one needs to consider the value of an observational Big Data study versus classical randomized controlled trials (RCT).

Prospective RCTs are often cited as the gold standard for evidence since by a careful study design, effects of hidden confounders can be minimized. But RTCs also have their shortcomings, in particular due to the way patients are selected for a study and due to the small sample size. RCTs are often done in relatively healthy homogeneous groups of patients, which are healthy except for the condition of interest, free of common diseases like diabetes or high blood pressure, and are neither extremely young or old [52]. If patients have several problems, treating them as if they were mutually independent might be bad in general, and information on treatment-treatment interactions are not be easily assessable through RCTs. Also, interplay between diseases like hypertension, high cholesterol and depression might not become apparent in RCTs. Since patients are difficult to recruit in general and the management of clinical studies is costly, sample size is often small. For the same reasons, findings need to be general and not personalized and there are long delays until a result is certain and can become clinical practice. It has been suggested that patient-reported outcome measures are often better predictors of long term prognosis [53]. Non-randomized, quasi-experimental studies are sometimes employed but provide less evidence than RCTs [54].

Big Data analyses, in contrast, consider data from a large variety of patients and potentially can draw conclusions from a

<sup>&</sup>lt;sup>2</sup>Deep Learning is one of the most exciting developments in machine learning in recent years. It is a field that attracts amazing talents with stunning successes in a number of applications. One of the driving forces in Deep Learning is DeepMind, a London based company owned by Google. DeepMind Health is a project in which U.K. NHS's medical data are analyzed. The agreement gives DeepMind access to healthcare data of more than a million patients [45]. A first outcome is the mobile app Streams, which presents timely information that helps nurses and doctors detect cases of acute kidney injury. Other notable commercial Deep Learning efforts with relevance to healthcare are Deep Genomics<sup>3</sup>, Entlitic <sup>4</sup> and Atomwise<sup>5</sup>.

much larger sample. Data are based on the natural population of patients, and conclusions can be personalized. For instance, with depressed diabetic patients, one would want to compare hospitalization rates between those taking antidepressants and those who were not, to determine if more patients should receive psychiatric treatment to help them manage their health. Currently such studies involve great efforts. In a future Big Data healthcare these questions could be answered by a simple database query [55].

Big Data analysis mostly concerns observational studies whose conclusions are considered by some to be statistically less reliable. The main reason is that hidden confounders might produce correlations, independent of a causal effect. Confounders are variables that both influence clinical decisions and, at the same time, outcome. One solution to minimize the effects of confounders are multivariate models where predictive models contain all those variables as inputs that were used in the decision making by the caregiver. Unfortunately, some of these variables might not be available for analysis, such as patient symptoms and patient complains, which both are often not well documented.

Data collection might introduce various forms of biases. Examples are batch effects, which might occur in the merging of data from different institutions; batch effects can be addressed by a careful statistical analysis [56], [57].

It is still unclear if physicians are ready to use evidence from Big Data. Generally accepted is the generation of novel hypotheses by Big Data studies, which are then clinically validated, although clinicians are critical towards hypothesis fishing [58]. Of course clinical studies are very expensive and would only be initiated with significant evidence from data and with the prospect of large benefits.

A desired and well accepted outcome is the discovery of novel patient subgroups based on risk of disease, or response to therapy, using diagnostic tests. These subgroups can then be the basis for a targeted therapy in precision medicine (see Section VII). For example, asthma is largely regarded as a single disease and current treatment options tend to address its symptoms rather than its underlying cause. It is now accepted that asthma patients can be grouped according to patterns of differential gene expression and clinical phenotype with group specific therapies [53].

A predictive or prescriptive analysis might output a prediction (e.g., prediction of some clinical end point), or a ranking or prioritization of treatments. Here the output might have been calculated based on many patient dimensions and this process might be difficult to interpret. Prioritization is currently still contrary to medical tradition and it remains to be seen if the medical profession will accept this aspect of a Big Data decision support system.

It is important to understand why machine learning solutions typically work with many inputs. In a perfect situation a diagnostic test can reveal the cause of a problem and the subsequent therapies solve or at least alleviate the problem. In reality, even with all advances in diagnostics, we are often still very far from being able to completely describe the health status of an individual. Technically, the health status of a patient consists of may aspects and only some

of these (i.e., some infections, some cancer types) can be inferred by specific diagnostic tests. In Big Data analysis one is partially doing "new medicine", i.e., one might address problems from novel disease subgroups or syndromes that cannot be detected unambiguously with existing diagnostic tests. Since the statistical model then implicitly needs to infer the latent causes from observed surrogates, the models often become high-dimensional, and their predictions become difficult to interpret by humans, although predictive performance might be excellent. This is an effect observed in a multitude of predictive machine learning applications in and outside of healthcare. The Big Data perspective is: If there are latent diseases, disease subgroups or syndromes, they leave traces in a large number of observable dimensions.

# IV. OUT WITH THE DATA

#### A. Introduction

In this section we focus on data that are leaving the clinic systems, i.e., data that are accessible to the payers, data that are collected in registries and data that are reported to healthcare agencies. Payers have a unique longitudinal view on patients and can perform statistical analysis on treatment efficiencies and outcome — for the optimization of their offerings, but also for the detection of fraud. Registries are valuable sources for epidemiological research. We will discuss Health information exchange (HIE), which refers to various activities around the mobilization of healthcare information electronically across organizations [5]. Data reported to healthcare agencies can be used for quality control and for policy optimization. As an example of the latter, we discuss the HITECH act, which is an attempt to improve the clinical system in the U.S. by encouraging an adoption of the EHR and its meaningful use via incentive programs. Finally, we discuss privacy and data safety.

### B. Data Accessible to Payers: Billing Data

The most common situation where data are leaving the clinic is when claims are filed with a payer, e.g., a health insurer or a health plan. Depending on the particular reimbursement rules in place, payers see data of varying levels of detail, quality and biases. Unfortunately, claims data may not fully reflect a patient's burden of illness [59], [60]. While the appropriateness of billing data to clinical research is often debated, many, many studies have used these data to guide clinical care, policy and reimbursement.

Claims data deliver a holistic view of patients across providers for a specific period of time, and it permits a patient centric view on health. Claims data also deliver direct and indirect evidence of outcome, e.g., by analyzing readmissions, and inform on cost efficiencies and treatment quality across providers. Payer organizations are increasingly interested in better understanding their customers, in this case their patients. Surveys, questionnaires, call center data, and increasingly social media including tweets and blogs are analyzed for gaining insights to improve quality of services and to optimize offerings.

A major concern is the detection and prevention of abuse and fraud. Healthcare fraud in the U.S. alone involves tens of billions of dollars of damages each year [61] and fighting fraud is one of the obvious activities to immediately reducing healthcare costs. Note that some forms of fraud actually do not only harm the payer but directly the patient (e.g., by unnecessary surgery) [62], [63]. Naturally there is a grey zone between charging for justified claims on the one side and abuse and fraud on the other side. Certainly, billing for services never provided, e.g., for fictitious patients or deceased patients, is clearly fraud, but if an expensive treatment is necessary or not in a case might be debatable. A 2011 McKinsey report stated that fighting healthcare fraud with Big Data analytics can be quite effective [2].

Technical solutions focus on the detection of known fraud patterns, the prioritization of suspicious cases and the identification of new forms of fraud. More sophisticated approaches use statistical models of clinical pathways and best practices to detect abnormal claims (against the population) and analyzes suspicious temporal changes in charging patterns within the same provider. In addition one can analyze different kinds of provider networks, where nodes are the providers and the links are common patients, analyzing homophily or "guilt by association" patterns. Another measure is the black listing of providers.

Most commercial systems use a combination of different strategies [61]. Despite all these efforts, and mostly due to the fragmentation in the system and a huge grey zone, it is estimated that only a few percentage of the fraud actually occurring is currently being detected.

# C. Registries

Disease or patient registries are collections of secondary data related to patients with a specific diagnosis, condition, or procedure.

There exist registries for dozens of problems<sup>6</sup>; the best known ones are cancer registries, which have become an invaluable tool for understanding and detecting cancer within the U.S. but also in many other countries.

Population-based cancer registries regularly monitor the frequency of new cancer cases (so called incident cases) in well-defined populations. The basis are case reports collected from different sources, e.g., treatment facilities, clinicians and pathologists, and death certificates. If an unexpected increase of cases can be observed in registries, hypotheses about possible causes are generated. These are then investigated in a second step by collecting more detailed data and performing further analysis. Registry data are critical to determining geographic and temporal cancer clusters and they can be used for the development and tracking of the most effective therapies and treatments. Population based registries can also monitor the effects of preventive measures. Public health officials use the data to make decisions on research funding and educational and screening programs [64].

In contrast to population registries, hospital registries are traditional means for research within a clinic or a clinic system using more detailed data about diagnosis, therapy and outcome. The quality of the conclusions that can be drawn from cancer registries critically depends on the completeness and the quality of data. Both might improve through the adoption of the EHR: Stage 2 of the HITECH act calls EHR reporting to cancer registries to support comparative effectiveness research. In October 2012, the University of Kentucky launched a first U.S. working model for EHR reporting of cancer cases to a state's cancer registry [64].

An important aspect is to guarantee that the electronic data transfer is safe and that proper precautions and safeguards have been implemented. If only summaries are reported, HIPAA violations (see Section IV-G) can be avoided. Note that with registries one obtains in-use data and one needs to be aware of possible confounders distorting the analysis (see discussion in Subsection III-G).

#### D. HIE

Health information exchange (HIE) refers to various activities around the mobilization of healthcare information in digital form and across organizations [5]. It is intended to regulate the electronic transfer of clinical and administrative information across diverse and often competing healthcare organizations [65]. HIE is also useful for public health authorities to assist in analyses of the health of the population

Several organizations have emerged to support the health information exchange efforts, both on independent and governmental/regional levels. These organizations develop and manage a set of contractual conventions and terms and develop and maintain HIE standards.

There are two main models for HIE data architectures. In a *centralized HIE* there is a central (or master) database which holds a complete copy of all of the records of every involved patient. In a *federated HIE* each healthcare provider is responsible for maintaining the records of their individual patients, as well as for data availability and common data standards.

Patient consent can be managed by an *opt-in* approach or an *opt-out* approach. In opt-in, a patient is not automatically enrolled into the HIE by default and generally must submit written permission for their data to be exchanged.

In opt-out, patients give implicit consent when they agree to use the services of a healthcare provider who is submitting data into an HIE. In this latter model a patient can request to opt-out of the HIE, generally with a written form.

A major goal is a nationwide health information network that will allow physicians quick access to their patients' complete medical histories without compromising their privacy. Another benefit is that the data can be used to support the learning healthcare system [6], [66].

# E. Care.Data

The U.K. has a national health service (NHS), which attempts to address many of the problems associated with the fragmented systems in the U.S. and in many other countries. A program called care.data was announced by the Health and Social Care Information Centre (HSCIC) in Spring 2013. The care.data

<sup>&</sup>lt;sup>6</sup>http://www.nih.gov/health/clinicaltrials/registries.htm

program was advertised to integrate health and social care information from different sources to analyze benefits and potential shortcomings of the NHS [67]. The data could be used in anonymized form by healthcare researchers, managers and planners, but also by parties from outside the NHS such as academic institutions or commercial organizations.

Stated goals of the project were

- to better understand diseases and treatments,
- to understand patterns and trends in public health and disease to ensure better quality care,
- to plan services that make the best of limited NHS budgets,
- to monitor the safety of drugs and treatments,
- and to compare the quality of care providers in different areas of the country.

Regardless of the question if the program was managed well or not, the experience shows which type of acceptance problems projects like these can encounter. An opt-out model was implemented where individuals were being informed that data on their health may be uploaded to HSCIC unless they objected, but the opt-out option was unclear. It was seen as a major problem that it was impossible for a patient to determine what the data will be used for, i.e., it was impossible to limit the use only for medical research by excluding insurance companies and pharmaceutical industry. Another issue was that the data was pseudomyzed, i.e., a unique patient identifier was used, and critics argued that this would not be a major hurdle for re-identification. People were worried that data were made accessible to consulting companies like McKinsey or PWC as well as pharmaceutical companies, like AstraZeneca. There was also concern that the police could access the data.

In October 2014 the program was reviewed by the Cabinet Office Major Projects Authority and it was concluded that it had "major issues with project definition, schedule, budget, quality and/or benefits delivery, which at this stage do not appear to be manageable or resolvable".

#### F. Incentive Programs

The wording is dramatic: Some argue that healthcare is undergoing the most significant changes in its history, driven by the spiraling cost of care, shifting reimbursement models, and changing expectations of the consumer. Reforming the healthcare system to reduce the rate at which costs have been increasing while sustaining its current quality might be critical to many industrialized countries. An aging population and the emergence of new, more expensive treatments will accelerate this trend.

It has been argued that by far the greatest savings could be achieved by population wide healthier lifestyles, which would largely prevent cardiovascular diseases and chronic conditions like diabetes. Chronic conditions account for an astounding 75% of healthcare costs in the U.S. [68], [69]. There is some hope that the proliferation of fitness and health apps might be greatly beneficial to population health (see Section VI).

Population health management tries to improve the situation by different measures such as a value-based reimbursement system causing providers to change the way they bill for care. The goal is to align incentives with quality and value. Instead of providers being paid by the number of visits and tests they order (fee-for-service), their payments are increasingly based on the value of care they deliver (value-based care). For those providers and healthcare systems that cannot achieve the required scores, the financial penalties and lower reimbursements will create a significant financial burden.

An important instrument in the U.S. is the Health Information Technology for Economic and Clinical Health Act, abbreviated HITECH Act. It was enacted under the American Recovery and Reinvestment Act (ARRA) of 2009. Under the HITECH Act, the United States Department of Health and Human Services (HHS) is spending several tens of billions of U.S.-dollars to promote and expand the adoption of health information technology to enable a nationwide network of electronic health records (EHRs). This network can then be the basis for informed population health management and for improving healthcare quality, safety, and efficiency, in general.

The general goals are to improve care coordination, reduce healthcare disparities, engage patients and their families, and improve population and public health, by, at the same time, ensuring adequate privacy and security.

The implementation is in three stages. An organization must prove to have successfully implemented and used a stage for a minimum of time before being able to move to a higher stage. If stages are successfully reached, financial incentives in Medicaid and Medicare are being paid. If stages are not reached, financial penalties can be implemented by both systems.

In Stage 1, the participating institutions do not only need to introduce an EHR but also need to demonstrate their meaningful use. The core set of requirements include the use computerized order entry for medication orders, the implementation of drugdrug, and drug-allergy checks, and the implementation of one clinical decision support rule. Also the protection of the electronic health information (privacy & security) needs to be demonstrated.

Stage 2 introduces new requirements, such as demonstrating the ability to electronically exchange key clinical information between providers of care and patient-authorized entities. Health information exchange (HIE) (see Subsection IV-D) has emerged as a core capability for hospitals for Stage 2.

Stage 3 of meaningful use is shaping up to be the most challenging and detailed level yet for healthcare providers. Among the elements are additional quality reporting, clinical decision support and security risk analysis. The Stage 3 rule lists clinical decision support as one of the eight key objectives. Unlike the Stage 1 which required one clinical decision support rule, Stages 2 and 3 specifically require the use of five clinical decision support interventions.

Although welcomed by many, there also has been criticism of HITECH related to the increased reporting burden and the focus on reporting requirements and not on outcomes.

The HITECH act provides many opportunities for analytics, for example in the development of certified tools which provide evidence that a provider is fulfilling the various meaningful use criteria.

Other incentive programs have been put in place as well. For example the Centers for Medicare & Medicaid Services (CMS)

provide incentives via the Hospital Readmission Reduction Program (HRRP). Incentives are paid if patients are not admitted to the same clinic within 30 days of release for the same problem.

The New York State Department of Health has instituted the Delivery System Reform Incentive Payment Program with the goal of transforming NY Medicaid healthcare delivery to reduce avoidable hospitalizations by 25%. More than \$8 billion will be paid out in incentive and infrastructure payments to 25 Preferred Provider Systems (PPSs) provided they meet this ambitious goal in 5 years. The 25 PPSs are each geographically local networks of varying size (from 100+ to near 500+) including hospitals, physician practices, imaging centers, rehab, and hospice, who would normally compete for patients, but have voluntarily come together to form trusted health networks (i.e., a PPS). They have agreed to share patient data and coordinate patient care to improve patient experience through a more efficient, patientcentered, and coordinated system. The PPSs have "signed up" for different targeted programs (e.g., targeting mental health, fetal-maternal heath, diabetes, pediatric asthma, etc.) depending on community health assessments they performed in their area.

Although population health management might seem to be slow moving and bland if compared to the more visible precision medicine initiatives, it has recently be argued, that the impact of the former might be dramatically greater, if one looks at the current state of the art [70], [71]. "Looking at diabetes, precision medicine may help a few scattered patients in the right clinical trials to tackle their Type 1 diabetes, but it may not prevent the 28 percent of undiagnosed Type 2 diabetics from experiencing adverse effects from a lack of treatment the way a robust risk stratification and predictive analytics program might," Bayer and Galea write [70].

#### G. Data Privacy, De-identification and HIPAA

Data breaches in the medical industry happen more often than expected [11]. A wake-up call was the February 2015 cyber attack on Anthem Health, which affected the personal information of 78.8 million people. Healthcare information has considerable value in the black market. Since, in general, even a major data breach does not affect revenue, organizations have few incentives to invest in digital security; thus, regulations are introduced to encourage security measures.

The storage, access and sharing of medical and personal information of any individual is addressed in the *HIPAA Privacy Rule*. The *HIPAA Security Rule* outlines national security standards to protect health data created, received, maintained or transmitted electronically. The latter is also known as ePHI (electronic protected health information) [72].

The HITECH Act supports the enforcement of HIPAA requirements by introducing penalties for health organizations that violate HIPAA Privacy and Security Rules. Any company that deals with protected health information must ensure that all the required physical, network, and process security measures are in place and followed.

#### V. THE PATIENT IN CHARGE

Patients become more active in taking charge of their own health and their health data (patient empowerment) and leave traces that can be analyzed to better understand population health and health concerns. On the down side, public traces can also be used to the patients' disadvantage and there is an increasing worry about bullying and social scoring.

# A. Leaving Traces

Web-based search is part of nearly everyone's life and is also the preferred venue to find out about one's health issues. Health related research often starts with Wikipedia, which is frequently consulted on health issues by both patients and health professionals. Wikipedia is undoubtedly an important source of information although quality issues have been raised [73]. There are a number of health specific portals (e.g., netdoctor, healthline, Yahoo Health, WebMD, whatnext.co and RevolutionHealth), some of which are managed by leading healthcare providers such as the Mayo Clinic and the Cleveland Clinic.

Other web services help patients find the right provider for their problems. Among them are commercial resources like *Healthgrades* and *ZocDoc* as well as government resources such as Medicare's *Hospital Compare* site. One can observe an increasing willingness to "shop for health" leading to the question of which company would become the "Amazon of healthcare" [74].

Similar to the general population, patients are increasingly active in social networks like Facebook and various blogs. There are also a number of social network services addressing specific health issues [75]. The motivation is obvious: Patients with the same problems want to communicate and exchange information. Problem-specific communities are organized by commercial and noncommercial web portals and special services can be provided to these groups by third parties.

Not just patients might want to organize themselves, but also clinics and healthcare professionals, and collaboration tools appear on the market.<sup>8</sup>

#### B. Analyzing Traces

Statistics on anonymized search query logs and traces in social media can be analyzed to inform public health, epidemiologists and policy makers. *Infodemiology* is a new term standing for the large-scale analyses of anonymized traces, which can potentially yield valuable results and insights. Infodemiology can support the early detection of epidemics, the analysis and modeling of the flow of illness and other purposes [76]. It can address public health challenges and can provide new avenues for scientific discovery [76].

A widely discussed example is the analysis of search query logs as indicators for disease outbreaks. The idea is that social media and search logs might indicate an outbreak of an infectious disease like a flu immediately, including detailed temporal-spatial information of its spread. Previously, such

<sup>&</sup>lt;sup>7</sup>DSRIP: http://www.health.ny.gov/health\_care/medicaid/redesign/docs/dsrip\_project\_toolkit.pdf)

<sup>&</sup>lt;sup>8</sup>https://bps-healthcare.siemens.com/teamplay/, http://www.cmtcorp.com/

outbreaks might go unnoticed for days of even weeks. But models have proven difficult. Google Flu Trends for example, predicted well initially but the fit was very poor later [77], [78].

Another application is the detection of adverse drug reactions, which could be improved by jointly analyzing data from the U.S. Food and Drug Administration's Adverse Event Reporting System, anonymized search logs and social media data [76]. The analysis of patients' traces has increasing importance in *pharmacovigilance*, which concerns the collection, detection, assessment, monitoring, and prevention of adverse effects with pharmaceutical products. Still there is little experience yet in the quality, reliability and biases in data generated from Web query logs and social network sites and conclusions should be drawn with great caution [79], [80].

There is also a danger in patients leaving traces in social media: When re-identified, traces can be aimed at making inferences about unique individuals that could be used to infer their health status. Many problems are associated, e.g., with social scoring in healthcare. [76] reports on a Twitter suicide prevention application called Good Samaritan that monitored individuals' tweets for words and phrases indicating a potential mental health crisis. The service was removed after increasing complaints about violations of privacy and imminent dangers of stalking and bullying. As pointed out by [76], health issues can also be inferred from seemingly unrelated traces. Simply changing communication patterns on social networks and internet search might indicate a new mother at risk for postpartum depression.

Another issue is that some companies are working together with analytic experts to track employees' search queries, medical claims, prescriptions and even voting habits to get insight into their personal lives [81]. Although HIPAA legislation forbids employers to view their employees' health information, this does not apply to third parties. A company which received public attention is Castlight, which gathers data on workers' medical information, such as who is considering pregnancy or who may need back surgery. Castlight's policy is to only inform and advice the individuals directly and only report statistics to employers.

Patient privacy issues are increasingly addressed by regulators, e.g., in the U.S. by the *Americans with Disabilities Act* (ADA) and the *Genetic Information Non-Discrimination Act* (GINA).

[76] points out the technical difficulties in protecting the citizens against violations, in the face of powerful machine learning algorithms which can "jump categories": Machine learning can enable inferences about health conditions from nonmedical data generated far outside the medical context [76].

# C. PatientsLikeMe

An openly commercial social network initiative is Patients-LikeMe [82], [83] with several hundred thousands of patients using the platform and addressing more than a thousand diseases. The majority of users have neurological diseases such as ALS, multiple sclerosis and Parkinson's, but PatientsLikeMe

is also increasingly addressing AIDS and mood disorders [84], [85].

PatientsLikeMe is not merely a chat board with self-help news but also collects quantitative data. It has designed several detailed questionnaires which are circulated regularly to its members. For example, epileptics can enter their seizure information into a seizure monitor. It has a survey tool to measure how closely patients adhere to their treatment regimen, but also scans language in the chat boards for alarming words and expressions. PatientsLikeMe offers a number of services. Together with the Massachusetts Eye and Ear Hospital it created a contrast sensitivity test for people with Parkinson's and hallucinations.

The business model of PatientsLikeMe is not based on advertising. Instead, the company has based its business model on aligning patient interests with industry interests, i.e., accelerated clinical research, improved treatments and better patient care. To achieve these goals, PatientsLikeMe sells aggregated, de-identified data to its partners, including pharmaceutical companies and medical device makers. In this way, PatientsLikeMe aims to help partners in the healthcare industry better understand the real-world experiences of patients as well as the real-world course of disease. Some of Patients-LikeMe's past and present partners include UCB, Novartis, Sanofi, Avanir Pharmaceuticals and Acorda Therapeutics.

## D. Managing Your Own Data

Consumers might not only want to research their health issues and communicate with others, but also possibly manage their own data.

If patients take responsibility for their own data, they must be able to store, manage and control the access to these data. By nature, this would overwhelm the patients' capabilities and commercial and noncommercial services realize some of the necessary functions [86]. The core is a personal health record (PHR) which is a patient centered assembly of all personal health information.

Among the earliest offerings is the Microsoft HealthVault, which addresses individuals who want to manage their own or their family's health. The HealthVault permits the storage and consolidation of a patient's life health information and enables the patient to give access to this information to selected parties. For example, the HealthVault keeps digital records of children's immunization records or an individual's medical imaging results and displays them to authorized parties whenever wanted. Doctors can send data and files right into an individual's HealthVault account. The site lets the users generate letters that can be sent to their healthcare professionals, outlining instructions, and security and encryption details. As discussed in the next section, a lot of healthcare and fitness related data are produced by mobile devices, and services like HealthVault offer convenient functionalities for managing, storing and analyzing those data. The World Medical Card and WebMD offer related services.

Naturally, due to privacy issues and their distributed nature, PHRs are difficult to use as part of an analytics project; nevertheless the rich information in a PHR can be used in a personalized advisory and alarming system.

<sup>9</sup>http://www.castlighthealth.com/

# VI. CONTINUOUS HEALTHCARE

With the tremendous technological progress and prevalence of mobile devices, the disruptive potential of mobile health (mHealth), and also, more general, technology-enabled care, is frequently being discussed [87], [88]. A new generation of affordable sensors is able to collect health data outside of the clinic in an unprecedented quality and quantity. This enables the transition from episodic healthcare, dominated by occasional encounters with healthcare providers, to continuous healthcare, i.e., health monitoring and care, potentially anytime and anywhere! Continuous healthcare certainly has the potential to create a shift in the current care continuum from a treatmentbased healthcare to a more prevention-based system: Many health problems can be prevented by a healthy life style and the early detection of disease onset, in combination with early intervention. However, the full potential remains to be unlocked as a 2012 Pew Research Center study about mobile health reveals [89]: While about half of smartphone owners use their phone to look up health information, only 1 in 5 smartphone users own a health app. Currently this exciting field is in a flux and opportunities, challenges and crucial factors for its widespread adoption are discussed in current research [90], [91], [92], [93].

#### A. Technological Basis

The technological basis of mHealth includes smart sensors, smart apps and devices, advanced telemedicine networks such as the optimized care network<sup>10</sup> and supporting software platforms. There is a broad range of new devices that have entered the market: smartphones, smart watches, smart wrist bands, smart head sets and Google Glass, among others. In the future, patient-consumers might use a number of different devices that measure a multitude of different signals: "headsets that measure brain activity, chest bands for cardiac monitoring, motion sensors for seniors living alone, remote glucose monitors for diabetes patients, and smart diapers to detect urinary tract infections" [11].

A Body Area Networks (BAN) is another form of a technological enabler with sensors that measure physiological signals, physical activities, or environmental parameters and it comes along with an internet-like infrastructure. BANs are, for example, being used to monitor cardiac patients and help to diagnose cardiac arrhythmias [94].

Add-ons to mobile devices such as lab-on-a-chip technologies are particular interesting technologies and might represent a new form of point-of-care devices. [95] presents a laboratory-quality immunoassay that can be run on a smartphone accessory and [96] present a 3D printed attachment for a smartphone for the detection of sickle cell disease.

Especially for developing countries with a limited infrastructure the potential of such technologies is tremendous.

From an engineering perspective, continuous healthcare is related to condition monitoring and predictive maintenance, enabled by smart sensors, connectivity and analytics — a combination often referred to as the internet of things (IOT).

By measuring and aggregating the signals from many different persons, machine learning algorithms can be trained to detect, e.g., anomalies and unexpected correlations that might generate new insights. Open source initiatives such as the Open mHealth<sup>11</sup> initiative are important enablers that could pave the way to overcome the data integration challenges.

# B. Use Case Types

1) Disease prevention: Smartphones are increasingly being used for measuring, managing and displaying lifestyle and health parameters, related, e.g., to weight, physical activity, smoking, and diabetes. Improving lifestyle and fitness of the general population has the potential to reduce healthcare costs dramatically and thus fitness and health monitoring might have dramatic positive impact on both population health and healthcare cost. In a recent statement, the American Heart Association (AHA) reviews the current use of mobile technologies to reduce cardiovascular disease (CVD) risk behavior [97]. CVD continues to be the leading cause of death, disability and high healthcare costs [97] and is thus a prime example for investigating the potential of mHealth technologies. The work investigates different tools available to consumers to prevent CVD, ranging from text messages (e.g. smoking cessation support), wearable sensors, and other smartphone applications. While more evidence and studies are needed, it appears that mHealth in CVD prevention is promising. The AHA strongly encourages more research.

2) Early detection: Many diseases can be treated best when discovered early and before they cause serious health consequences. Early detection can happen at the population level or at the individual level. [87] highlights an early warning system for disease outbreaks caused by illness related parameters such as environmental exposure or infectious agents. On the individual level, the previously mentioned Body Area Network is a major enabler for early detection of abnormalities. So-called smart alarms can be understood as another form of early detection on the individual level.

Smart alarms cover a range of applications, such as the monitoring of heart activity, breathing, and potential falls, and are especially relevant to the elderly [94].

The company AliveCor<sup>12</sup> is offering a mobile ECG that is attached to a mobile device (either smartphone or tablet). The attached device creates an ECG that is then recorded via an app. The mobile ECG is cleared by the FDA and can also detect atrial fibrillation, a leading cause of mortality and morbidity. AliveCor states that the device has been used to record over five million ECGs, and that these data are then the basis for training an anomaly detection algorithm.

3) Disease management: Healthcare costs can be reduced when the patient is monitored at home instead of in the clinic and if physicians can optimize care without the need to call in the patients for a medical visit. Some hospitals and clinics collect continuous data on various health parameters as part of research studies [11]. Especially the management of chronic

<sup>10</sup>http://www.optimizedcare.net/

<sup>11</sup> http://www.openmhealth.org/

<sup>12</sup>http://www.alivecor.com/

diseases can benefit from continuous healthcare. In a recent review [98], the authors screen systematically for randomized clinical trials that give evidence about better treatment adherence when using mHealth technologies. Applications range from simple SMS services to video messaging with smartphones and other wireless devices. They conclude that there is, without doubt, high potential for these technologies but, as the evidence in the trials was mixed, further research is needed to improve usability, feasibility, and acceptability.

4) Support of translational research: With hundreds of millions of smartphones in use around the world, the way patients are recruited to participate in clinical studies might change dramatically. In the future patients might be able to decide themselves if they want to participate in a medical study and they might be able to specify how their data will be used and shared with others.

Major research institutions have already developed apps for studies involving asthma, breast cancer, cardiovascular disease, diabetes and Parkinson's disease. One interesting use case is the control of disease endpoints in clinical trials with mHealth technologies. As a concrete example, Roche developed an app to control or measure the clinical endpoints of Parkinson disease. The app, which complements the traditional physician-led assessment, is currently used in a Phase I trial to measure in a continuous way disease and symptom severity. The app is based on the Unified Parkinson's Disease Rating Scale (UPDRS), which is the traditional measurement for the disease and symptom severity. The test, which takes about 30 seconds, investigates six endpoint-relevant parameters and involves a voice test, balance test, gain test, dexterity test, rest tremor tests and postural tremor.

The Clinical Trials Transformation Initiative<sup>14</sup>, an association representing diverse stakeholders along the clinical trial space, is envisioning the next generation of clinical trials. Recently, the initiative has launched a mobile clinical trials program to investigate how mobile technologies and other off-site remote technologies can further facilitate clinical trials.

# C. Selected Projects

Many different projects have begun involving clinics, research institutes and technology providers. In a recently started pilot between the MD Anderson Cancer Center and Polaris Health, Apple Watches are collecting data from breast cancer patients [99]. According to a Polaris statement, data to be collected include treatment side effects, information about sleep behavior, levels of physical activity, and patient mood. Researchers will combine this information with EHR data from the patients and health data of other breast cancer patients to create new insights.

Another example demonstrates the great potential for developing countries. Medic Mobile, <sup>15</sup> a non-profit technology company, has developed a software platform that is used in 23 countries in Africa, Latin America, and Asia to improve

care in rural areas. The use cases of the platform range from antenatal care, childhood immunization, disease surveillance, and drug stock monitoring. For antenatal care, the organization reports on their homepage that approximately 500.000 people have been covered in the countries Bangladesh, Kenya, and Nepal. Over 1.800 community health workers are using their smartphones to register women in a central database once they are pregnant. Automated text messages are then sent to organize appointments, and health workers can register any potential danger signs.

Japan Post, one of Japan's largest insurers, joins forces with IBM and Apple to address issues of an aging generation [100]. They will be designing app analytics and cloud services around the smartphone to help to connect millions of seniors with their families but also to healthcare services. The project will help Japan Post to both know more about its customers and to improve the health and wellness of its seniors, thus allowing individuals to live potentially longer, healthier and more independently.

The Quantified Self movement [101] uses sensors to put a person's daily life into data by self-tracking biological, physical, behavioral or environmental signals [101]. The community is supported by a company of the same name.<sup>16</sup>

## D. Implications for the Clinical Setting and the Doctor's Office

Some hospitals and insurers have already recognized the willingness of patients to use telemedicine services [102] and are offering video consultations —a contemporary "house call" to patients via Skype and other internet conferencing systems. "In the way that video calls and instant messaging revolutionized the way people communicate with others, now health systems are exploring how e-health consultations for routine ailments can relieve the pressure on primary care systems that are functioning beyond capacity," Blumenthal writes [11]. Some patients find these e-visits to be cheaper and more convenient than visits to their doctor's office. About 55% of patients recently asked in a survey would send a photo of their skin to a dermatologist for consultation.<sup>17</sup> Researchers say more evidence is needed to understand if virtual medical visits will actually reduce costs or improve health outcomes. But the demand among patient-consumers is there and some large insurers have begun to pay for these virtual consultations [11].

#### E. Regulatory Implications

The continuous healthcare ecosystem has brought together stakeholders that were previously more or less unconnected and now have to interact. For instance in the U.S., certain app developers suddenly have to deal with premarket notification or so-called 510(k) clearance processes from the FDA. The driving question here is which type of mHealth applications fall under FDA's jurisdiction over medical devices. Indeed, different classifications of "mobile medical applications" and

<sup>13</sup>http://www.roche.com/media/store/roche\_stories/roche-stories-2015-08-

<sup>14</sup>http://www.ctti-clinicaltrials.org/

<sup>15</sup> https://medicmobile.org/

<sup>16</sup>http://quantifiedself.com/

<sup>&</sup>lt;sup>17</sup>http://www.pwc.com/us/en/health-industries/healthcare-new-entrants/assets/pwc-hri-new-entrant-chart-pack-v3.pdf

according FDA guidances now exist, but they do not appear to be finalized yet.

While it is the traditional responsibility of the FDA to oversee the safety and effectiveness of medical devices (also including certain types of mobile apps), some politicians and industry representatives are afraid that innovation is hampered by regulatory oversight. However, first warning letters to doctor's had to be sent out where mobile medical apps showed unexpected behavior; another case revealed that about 52 adverse event reports in the FDA's reporting database were generated for one specific diabetes app within two years [103]. Clearly, further intensive dialogue between stakeholders is needed. [103] describes in detail the challenges that come along with the regulation of mHealth technologies, together with potential alternative regulatory scenarios.

# F. Conclusion

In conclusion, the potential benefits of continuous healthcare are tremendous. Of course many challenges remain: will it be possible to solve major issues with data privacy? Will it be possible to maintain population interest in the long run or are health apps just a temporary phenomenon? Will there be sustainable business models? Will it be possible to find technical solutions for the data integration challenges? What will be the eventual clinical impact of digital mHealth?

#### VII. GETTING PERSONAL

# A. Precision Medicine is Changing Healthcare

Maximizing the positive effect of a healthcare intervention by concurrently minimizing adverse side effects has always been the dream of individualized healthcare. Over the last decades it became clear that this goal cannot be achieved with insights from conventional studies alone, which have been focusing on empirical intervention efficacy and side effects in large patient study groups. The reason is that, due to the biological diversity of individuals, environment and pathogenesis, any incident of a complex disease is like no other. Precision medicine, personalized medicine, individualized medicine and stratified medicine —terms we will use interchangeably— all refer to the grouping of patients based on risk of disease, or response to therapy, using diagnostic tests. Precision medicine thus refers to the idea to customize healthcare, with medical decisions, practices, and procedures being tailored to a patient group. In its most extreme interpretation, this leads to the "n=1" principle, meaning that therapy should be tailored to the patient's individual characteristics, sometimes referred to as the "unique disease principle" [104].

Without question, the most important milestone for the realization of a personalized medicine was the publication of the reference sequence of the human genome about 15 years ago [105], [106]. In the following years, the patient's genomic profile, supplemented with other molecular and cellular data, became the basis for a dramatic progress in the understanding of the molecular basis of disease. The impact of this knowledge is not limited to research: As new analytical methods like next generation sequencing (NGS) and new proteomic platforms

bring cost down, molecular data will increasingly become part of clinical practice.

With growing data sets, increasingly complex phenomena, even with weak associations, can be discovered and validated. Genome-wide association studies (GWAS), with more than a million attributes collected from up to several thousands individuals, are good examples. The main goal is to link the generated data to clinically actionable information. The vision of a *real-time personalized healthcare* is the rapid and real-time analysis of biomaterials obtained from the patients based on newest research results in a network of research labs and clinics. Research and clinical applications go along with a huge increase in volume and variety of data available to characterize the physiology and pathophysiology.

The insights in the biological causes of disease might lead to a more meaningful categorization of disease, at some point in the future replacing medical codes, which were mostly developed based on clinical phenotyping [53].

By far the greatest efforts in precision medicine have been devoted to cancer (oncology), but precision medicine becomes increasingly relevant to other medical domains, e.g., the central nervous system (e.g., Alzheimer's and depression), immunology/transplant, pre-natal medicine, pediatrics, asthma, infectious diseases and cardiovascular [107].

### B. Understanding Disease on a Molecular Level

In the last decades, a lot of attention has been focusing on understanding the genetic causes of disease.

Monogenetic disorders with a high penetrance have been linked to mutations of single inherited genes. The causative genes of most monogenic genetic disorders have now been identified [108].

Monogenetic diseases are relatively rare and attention has shifted largely to *complex diseases*: Most common diseases, including most forms of cancer, are based on an interaction of several factors including a number of inherited genetic variations, one or several mutations acquired during cell life time, as well environmental factors. Consider, for example, that worldwide approximately 18% of cancers are related to infectious diseases [109]. Due to the complex interplay of several factors, these diseases show, what has been termed, "missing heritability".

Insights into inherited genetic cell disorders are obtained from germline DNA, typically obtained from blood cells. Genome wide association studies (GWAS) examine the correlation between germline genetic variations and common phenotypic characteristics, such as breast cancer [110]. The likelihood of a person developing a disease in their lifetime can sometimes be predicted according to germline DNA profiles, permitting early intervention and possibly preventing an outbreak of the disease. With the establishment of next generation sequencing (NGS), in the future the whole genome might be decoded for costs in the order of a few hundred U.S. dollars and this will make clinical genome analysis much more common. Eventually, the increasing use of genome sequencing will lead to better insights into which diseases can be explained by genetic variance and could revolutionize molecular medicine for some diseases.

Additional genetic variations of interest are those acquired during the lifetime of somatic cells, which comprise all cells that form an organism's body, excluding the germ cells. As genetic alterations accumulate, the somatic cell can turn into a malignant cell and form a cancerous tumor. Genetic profiles (mutations and amplifications) of somatic cancer cells are obtained from analyses of tumor biopsies. Distinct mutations and gene amplification patterns can be linked to clinically relevant characteristics, such as prognosis or therapy response [111]. In some cases the tumor is easily accessible, however in other cases, as for tumors or metastases of certain organs (e.g. brain, liver, lung), a biopsy is not standard of care. In those cancer patients, the access to the material from which the genomic information could be obtained is difficult. Recently, novel methods have been developed that permit the analysis of alternative sources of tumor material, such as circulating tumor cells (CTCs). These are cancer cells that have shed into the blood stream from a primary tumor. CTCs can constitute seeds for subsequent growth of additional tumors (metastasis) in distant organs, triggering a mechanism that is responsible for the vast majority of cancer-related deaths. The analysis of CTCs has been called a "liquid biopsy". Also circulating tumor DNA (ctDNA) was found to resemble the tumors genomic profile, being useful for cancer detection and prediction of therapy efficacy [112].

So far we have been focusing on DNA. The transcription of RNA from DNA is called gene expression. This step plays a crucial functional role, because RNA is translated directly into functional proteins. Furthermore RNA has regulatory functions, of which many are not yet fully understood. Transcriptomics is the study of transcriptomes (RNA molecules, including mRNA, miRNA, rRNA, tRNA, and other non-coding RNA), their structures and functions. DNA microarrays (which, despite their name, really test for RNA) and RNA-seq (RNA sequencing) can reveal a snapshot of RNA presence and quantify cellular activities at a given moment in time. In some cancers, such as breast cancer, the expression of some genes has already been proven to be of great clinical relevance. Increasingly, genomewide gene expression analyses are becoming available to characterize cancer diseases [113].

Whereas the genome contains the code, the proteins are the body's functional worker molecules. Several methods like immunohistochemistry and enzyme-linked immunosorbent assays (ELISA) are used in clinical practice for protein analysis. In research, and recently also in clinical tests, mass spectroscopy is used to determine many proteins in a tissue, opening this field for high throughput and big data approaches [114]. Increasingly, protein microarrays are used as a high-throughput method to track the interactions and activities of many proteins at a time.

While the transformation of genetic information into functional proteins is recognized as being clinically highly relevant, the clinical relevance of other "omics" fields is still under investigation. Epigenomics, metabolomics and lipidomics are three further levels of systems biology which might be unraveled by big data analyses. Epigenetic changes modify genes on a

molecular level, such that expression is altered; the analysis of the effects of these modifications is part of current research. Metabolomics concerns chemical fingerprints that specific cellular processes leave behind, in particular, the study of their small-molecule metabolite. Lipidomics focuses on cellular lipids, including the modifications made to a particular set of lipids, produced by an organism or system.

The environment is increasing the number of possible interactions that play a role in the etiology (i.e., disease cause) and pathogenesis of a disease <sup>19</sup>. The exposome encompasses the totality of human environmental (i.e. non-genetic) exposures from conception onwards, complementing the genome. Disease often involves several factors. For example, scientists believe that, for most people, Alzheimer's disease results from a combination of genetic, lifestyle and environmental factors that affect the brain over time. <sup>20</sup> Only in less than 5 percent of cases, Alzheimer's is caused by specific genetic changes that, by themselves, virtually guarantee a person will develop the disease. <sup>21</sup>

As a medical field, molecular medicine is concerned with the molecular and genetic problems that lead to diseases and with the development of molecular interventions to correct them. A better understanding of the underlying molecular mechanisms of diseases can lead to great advances in diagnostics and therapy. In particular, cancer subgroups can be determined by omics profiles and the most effective treatment with smallest adverse effects can be determined for each subgroup. This concept is at the center of precision medicine.

To give insight in what is clinically relevant today, consider the concrete example of breast cancer. Molecular techniques have changed our understanding of the basic biology of breast cancer and provide the foundation for new methods of "personalized" prognostic and predictive testing. Several molecular markers are already established in clinical practice such as high penetrance breast cancer causing genes (BRCA1 and BRCA2) [116], [117]. Also the characterization of the tumor is driven by molecular markers such as estrogen receptor, progesterone receptor and a genetic alteration, the HER2 amplification [118]. Since the biological signals of those markers are quite strong, they were discovered already in the 90's of the last century, even before high throughput molecular analysis became a reality. Now, more than 15 years after the primary publication of the human genome, many levels of biology (DNA, RNA, Protein, Epigenetics, miRNA, ...) can be analyzed at relatively low cost, revealing detailed and comprehensive insight into the biology of a cell.

<sup>&</sup>lt;sup>18</sup>This is a test that uses antibodies and color change to identify a substance.

<sup>&</sup>lt;sup>19</sup>http://www.genome.gov/27541319

<sup>20</sup>http://www.mayoclinic.org/diseases-conditions/alzheimers-disease/basics/causes/con-20023871

<sup>&</sup>lt;sup>21</sup>Reality is even more complex: there is also heterogeneity within a particular tumor. The hypothesized *cancer stem cell model* asserts that within a population of tumor cells, there is only a small subset of cells that are tumourigenic (able to form tumours). These cells are termed cancer stem cells (CSCs), and are marked by their ability to both self-renew and differentiate. One assumes a process of natural selection within a given tumor which also would explain why cancer is so difficult to fight: a treatment might eliminate one strain giving room for another strain to develop. It has been argued that this could be a major problem for the vision on a personalized medicine [115]. An alternative but related explanation is the *clonal evolution model*.

A particular role for understanding breast cancer on the molecular level play the efforts around "The Cancer Genome Atlas" (TCGA). It was one of the first Big Data efforts that compared the genetic information of the tumor with the genetic information of the blood on a large scale for each single of the three billion base pairs. See also Section VII-E. This project could, for the first time, describe systematically, which genes will mutate in the course of the pathogenesis of a healthy mammary cell to a breast cancer cell [111].

#### C. Molecular Diagnostics and Drug Therapy

The need for a precision medicine is quite apparent when looking at the limited drug response rates, as published research from the early 2000s reveals [119]. Thus alternatives to the traditional "blockbuster" models are needed [53].

The *diagnostic* part of precision medicine heavily relies on biomarkers. In molecular diagnostics, the term biomarker refers to any of a patient's molecules that can be measured to assess health and that can be obtained from blood, body fluids, or tissue. Biomarker testing is at the center of personalized medicine and tests are specific, e.g., to DNA, RNA or protein variations. Biomarkers may test if certain proteins are overactive, in particular if they help to promote cancer growth and therapy, and may be based on the identification of a molecule (a *drug target*), often a protein, whose activity needs to be modified by a drug.

Pharmaceutical research tries to find drugs, so called targeted drugs, that bind the drug target with the goal to influence underlying disease mechanisms. Targeted therapy uses a number of different strategies to fight tumors. Some targeted drugs block (inhibit) proteins that are signals for cancer cells to grow. Drugs called angiogenesis inhibitors stop tumors from making new blood vessels, which greatly limits their growth. Immunotherapy is a treatment that uses the body's own immune system to help fight cancer, e.g., uses the patient's immune system to attack tumor cells. A strategy is to generate antibodies (e.g., monoclonal antibodies) which are man-made versions of large immune system proteins that bind to very specific target proteins on cancer cell membranes. To give an example, the protein HER2 is a member of the human epidermal growth factor receptor family and its overexpression plays an important role in certain forms of breast cancer; HER2 is the target of the monoclonal antibody trastuzumab.

Biomarkers are relevant in companion diagnostics, which are diagnostic tests used as companions to a therapeutic drug to determine its applicability, e.g., efficacy and safety, to a specific patient.<sup>22</sup> Companion diagnostics are co-developed with drugs to aid in selecting or excluding patient groups for treatment.

While most drugs have been approved for very specific diseases, they might also sometimes be effective in other diseases. One reason is that the targets in both diseases might have the same alterations. The application of known drugs and compounds to treat new indications is called drug repurposing. Analytics can play a role in finding good candidates [120], [121]. A well known case is the pain medicine Aspirin, which was

found to be effective in treating and preventing heart disease. In cancer, as another example, it could be shown that a drug that works against a mutated gene in melanoma is also active in other cancers if the respective mutation in BRAF is found [122]. The main advantage of drug repositioning over traditional drug development is that —since the repositioned drug has already passed a significant number of toxicity and other tests— the drug's safety is known and the risk of failure for reasons of adverse toxicology is reduced. Thus, the introduction of a specific drug for a new disease is greatly simplified.

# D. Implementing Precision Medicine

As a major milestone, a first insurer has begun to cover the cost of the sequencing of the full germline and tumor genomes of cancer patients<sup>23</sup>. Despite the great perspectives of precision medicine, it still faces many challenges. The implementation will require changes and improvements on many levels, reaching from technology developments (one genome can comprise up to 400GB of data) over social and ethical challenges to legal implications and the need for large scale educational programs for patients, physicians, researchers, healthcare providers, insurance companies and even politicians [123].

The abundance of data and possibilities to join information sources raises the question, whether current rules for intellectual property, reimbursement and personal privacy have to be adapted to personalized medicine.

Regulatory authorities have already acknowledged those challenges and released a report: "Paving the Way for Personalized Medicine: FDA's role in a New Era of Medical Product Development" [124]. In this report the FDA describes a framework of how to integrate genomic medicine into clinical practice and drug development. Steps to implement precision medicine include the development of regulatory scientific standards, research methods, and reference material [124]. Implementing and commercializing precision medicine will demand new standards with regard to the protection of patients' privacy and that of their families. Data protection issues arise especially for healthy individuals who have genetic predisposition for a disease or patients who have a genetic alteration (either germline or somatic) and who are thought to be non-responsive to standard treatments: In some cases the person, for which the molecular data were created, might not want to know the complete interpretation of those results. An important milestone regarding privacy issues in the U.S. was the Genetic Information Nondiscrimination Act (GINA) in 2008 that protects American citizens from being discriminated based on their genetic information with respect to employment and health insurance.

## E. Big Data in Molecular Research

The aim is to use the newly gained insight into etiology, pathogenesis and progression of diseases for novel treatments and prevention. Large international consortia were formed

 $<sup>^{22}</sup> http://www.fda.gov/MedicalDevices/Products and Medical Procedures/\ In Vitro Diagnostics/ucm 407297.htm$ 

<sup>&</sup>lt;sup>23</sup>http://www.reuters.com/article/ca-nanthealth-idUSnBw116104a+100+BSW20160111

over the last years integrating data from not seldom several hundreds of thousands of individuals to compare genetic and environmental information of healthy individuals with diseased patients. Several of those consortia have built super-consortia merging data and biomaterials of several large scale consortia. One example is the OncoArray Network<sup>24</sup> GWAS study, in which more than 400,000 individuals are genotyped for more than 570,000 genetic variants. Diseases included in this effort are breast cancer, ovarian cancer, colon cancer, lung cancer and prostate cancer. GWAS studies examine the correlation between germline gene variations and phenotypic characteristics and explain a certain amount of attributable risk for a disease within a population. For the case of breast cancer, GWAS led to the discovery of around 100 risk genes [125]. For the individual the statistical effects are rather small and implementation into healthcare is highly dependent on programmes which would utilize this information in an epidemiological way, i.e. by selecting patients for individualized prevention or early detection of a disease. This strategy requires tens if not hundreds of thousands or millions individual decisions in a population, which will require highly scalable Big Data technology.

The 1000 Genomes Project [126], launched in 2008, was an effort to sequence the genomes of at least one thousand anonymous participants. Many rare variations were identified, and eight structural-variation classes were analyzed. It is followed by the 100,000 Genomes project, which was launched in 2013. It aims to sequence 100,000 genomes from UK's NHS patients by 2017 and it is focusing on patients with rare diseases and more common cancers.<sup>25</sup>. An interesting and less costly alternative is the distributed collection of genomic data from patients who donate their decentrally analyzed genome to central projects.<sup>26,27,28</sup>. From a data management perspective, these decentralized approaches require innovative ways of storing and analyzing huge amounts of data employing distributed computing<sup>29</sup>.

Biobanks are great sources for molecular research. Biobanks store biological samples (often cancerous tissue) for use in research like genomics and personalized medicine [127].

As stated before, complex diseases involve a number of causes. Unfortunately, to study the interaction of disease causes involving, for example, several gene variations requires even larger sample sizes. Similarly, the study of complex patterns behind the spatio-temporal disease progression requires the acquisition and management of huge data samples [128].

# F. Digitization Challenges in Precision Medicine

Recent publications [129], [130] estimate that storage needs for molecular data will exceed by far those of Twitter or YouTube, which is of great concern to researchers and health-care professionals alike.

This perception is supported by the many large scale population-based initiatives (e.g. the aforementioned Genomics England 100K project or the NIH precision medicine initiative) that will collect genomic and other biomedical data from individuals for the next 5-10 years. A comprehensive and recent overview of these cohort studies from publicly or private funded entities can be found in [56]. The experiences gained from these initiatives will reveal interesting insights and lessons learned about data management of genomic and other "omics" data (e.g. transcrpitomics, proteomics, metabolomoics, epigenomics), emerging standards, and data privacy topics such as informed consent.

To consistently improve patient outcome and medical value, it will become very important to bridge the gap between all the previously mentioned "omics" data and clinical outcome. Indeed clinical sequencing for advanced patient diagnosis is becoming more and more common, but many questions still remain, e.g., what parts of the genomic data should become part of the EHR records? Here, important consortia such as emerge (Electronic Medical Records and Genomics) and CSER (Clinical Sequencing Exploratory Research) will hopefully pave the way towards a more integrated view of genomics in the clinic [131]. Structuring, organizing, synchronizing different terminologies across clinical data repositories is the prerequisite to make clinical data meaningful. In that context companies such as Flatiron Health have developed powerful tools and processes to tackle data integration challenges and offer structured knowledge bases that can yield new insights.<sup>30</sup>

In many current efforts, data are aggregated across many patients with the goal of developing Clinical Decision Support (CDS) systems. The American Society of Clinical Oncology (ASCO) launched a program named CancerLinQ that envisions to learn not only from trial data but also from the mass of EHR records. A goal is that doctors get support in their decision making by matching their patients' data with outcomes of patients across the U.S. Patients gain confidence if their treatment decisions are based on their personal profile and on the shared experiences of similar cancer cases across the U.S. Finally, researchers can access this massive amount of de-identified health information to generate new hypotheses for research. To make CancerLinQ's vision happen, several different data types and technologies have to be orchestrated ranging from longitudinal patient records, cohort analyses, quality metrics, to interactive reporting and text analytics [132]. Interoperability between different EHR systems will be another crucial success factor for the CancerLinQ initiative.

# G. Traditional IT Players are Entering Precision Medicine

The outlined data management and analytics challenges in precision medicine are being addressed by a number of established IT companies. Here are some examples.

SAP has teamed up with American Society of Clinical Oncology (ASCO) to implement CancerLinQ [133], [132]. SAP's in-memory technology platform SAP HANA will play a crucial role in providing the infrastructure and algorithms to

<sup>&</sup>lt;sup>24</sup>http://epi.grants.cancer.gov/oncoarray/

<sup>&</sup>lt;sup>25</sup>https://www.theguardian.com/politics/2013/jul/05/health-jeremy-hunt

<sup>&</sup>lt;sup>26</sup>http://datascience.columbia.edu/donate-your-genome-science-learn-more-about-your-ancestry-health

<sup>&</sup>lt;sup>27</sup>http://www.personalgenomes.org/

<sup>&</sup>lt;sup>28</sup>https://dna.land/

<sup>&</sup>lt;sup>29</sup>https://arvados.org/

<sup>&</sup>lt;sup>30</sup>http://fortune.com/2014/07/24/can-big-data-cure-cancer/

analyze the vast amounts of diverse data to provide clinical decision support.<sup>31</sup>

IBM with its Watson technology [134], [135] has recently started a collaboration with the New York Genome Center (NYGC) to generate and analyze the exome, complete genome data, and epigenetic data linked to clinical outcomes from participating patients. The partners plan to generate an open knowledge base using the generated data<sup>32</sup>.

Dell is partnering with the Translational Genomics Research Institute (TGen) to tackle pediatric cancer in Europe and in the Middle East. In addition, Dell recently announced that its Cloud Clinical Archive —currently storing over 11 billion medical images and around 159 million clinical studies from multiple healthcare providers— will support storage and management of genomic data. The long term goal will be to combine medical imaging diagnosis with advanced genomics to impact patient care.

Intel is also looking into the precision medicine space. Saffron, a cognitive computing company that Intel acquired in 2015, is studying how users can gain additional insights from above mentioned Dell's Cloud Clinical Archive. The company is also offering Natural Language Processing capabilities and the platform can be compared to IBM Watson's offering. In addition, within the context of Barack Obama's Precision Medicine Initiative, Intel launched a Precision Medicine Acceleration Program<sup>33</sup>.

Microsoft also supports the U.S. government's Precision Medicine Initiative by hosting genomic data sets in Microsoft's Azure cloud platform by end of 2016 free of charge. <sup>34</sup>

Amazon Web Services (AWS) is offering HIPAA-compliant cloud storage and data security. Therefore AWS often functions as a backbone of genomics data management platforms and several companies such as Seven Bridges or DNAnexus rely on the AWS technology. As a concrete example, the Cancer Genomics Cloud (CGC), which includes the well-known "The Cancer Genome Atlas" (TCGA), is operated by Seven Bridges and runs on the AWS cloud.

Alphabet Inc. is investing heavily in precision medicine. This happens mainly either through the many investments taken by Google Ventures or by own research and development activities from subsidiaries such as Verily or Calico. Investments in companies related to precision medicine from Google Ventures include Flatiron Health, Foundation Medicine, and DNAnexus among others. Among Google's initiatives are, e.g., Google Genomics or the Google Baseline Study. Google Genomics is Google's HIPAA-compliant cloud platform for storing and managing genomic data; besides offering access to publicly available data sets such as the TCGA, customers can load their own genomic data sets and run analyses on the data through the offered API. The Google baseline study aims to collect

different types of data such as molecular, imaging, clinical and data related to patient engagement to understand patterns that are typical for healthy individuals.

All these efforts illustrate that information technology is moving quickly into personalized healthcare and therefore will be a main enabler to realize the goals of precision medicine.

# H. A View to the Future: a Truly "n=1"-Medicine

Dramatic improvements in the quality and speed of genomic sequencing and analysis as clinical diagnostic tools for individual patients, combined with the innovations propelling immuno-oncology, are paving a new era of truly personalizing the treatment of cancer. At the heart of these prospects are the newfound abilities to rapidly identify and target tumor cells with specific DNA mutations unique to each cancer patient. The products of mutated genes, encoding altered proteins, are so-called "neoepitopes" and serve as the molecular address to direct and redirect immune cells for killing the tumor cells and for procuring long term immunity. Neoepitopes are defined as unique genetic alterations that result in unique novel proteins. They are found specifically in a patient's tumor (but not in normal tissue) and can be targeted by the immune system to attack the tumor with minimal off target toxicity.

It is highly unlikely that the same neoepitopes occur in other patients, and if so only in small groups of patients. The generation of drugs to specific neoepitopes in real-time is a vision of a real-life "n=1" medicine [136], [137].

Identifying neoepitopes for each patient is made possible by high-throughput whole genome or exome sequencing and by the direct comparison of abnormal tumor DNA with each patient's own normal DNA. This widens the search for drugable targets (neoepitopes) in the >99% of the genome deemed untargetable or unimportant by panel sequencing and reduces the significantly high false positive error rates associated with tumor-only sequencing techniques [138]. To increase the precision in individualizing treatments, which are targeting neoepitopes, further requires a confirmation of the expression of the mutated genes, thus avoiding another potential pitfall of false positive errors and the potential for the altered protein to induce immunogenicity.

If a tumor is found to express unique neoepitopes, they can serve as a "molecular address" for the immune system. Therefore there is a good rationale that the neoepitope can be delivered to the immune system by an immunogenic vehicle like a vaccinating virus. One such vehicle is the adenovirus which may be engineered to express within its DNA many neoepitopes, and, upon injection, can locally infect dendritic cells of the immune system which then present an identified neoepitope to the immune effector cells and trigger an immune response against the tumor cells. Despite great promise, the use of adenovirus or any other foreign delivery vehicles remains hindered due to the pre-existence or the induction of neutralizing antibodies against them by the patient's immune system. This limitation has been overcome by engineered adenoviruses which are capable of safely vaccinating and re-vaccinating against hundreds of neoepitopes and tumor associated antigens despite pre-existing immunity against adenoviruses [139]. Remarkable

 $<sup>^{31}</sup> https://connection.asco.org/magazine/features/cancerlinq%E2%84%A2-takes-big-leap-forward$ 

<sup>32</sup>https://www.genomeweb.com/informatics/ibm-nygc-expand-partnership-new-pilot-cancer-study

<sup>&</sup>lt;sup>33</sup>https://www.whitehouse.gov/the-press-office/2016/02/25/fact-sheet-obama-administration-announces-key-actions-accelerate

<sup>34</sup>https://www.whitehouse.gov/the-press-office/2016/02/25/fact-sheetobama-administration-announces-key-actions-accelerate

results have thus far been published demonstrating the delivery of tumor-associated antigens by engineered adenoviruses in a cohort of late-stage colorectal cancer patients [140].

A more recent development has been the engineering and application of immune cells (T-cells and NK-cells) that express antibodies on their surface as part of a "chimeric antigen receptor" (CAR) for direct targeting of tumor cells expressing their cognate antigens. One particular approach, an off-the-shelf human NK cell line dubbed NK-92, is engineerable to produce innumerable CARs. These cells are now being engineered to produce CARs targeting neoepitopes discovered to be expressed by individual cancer patients' tumor cells, thus enabling a novel, truly personalized immunotherapeutic approach to fight cancer. For this and many other reasons, the discovery of neoepitopes has the potential to be a watershed moment in the war against cancer. These examples show that the utilization of the immune system to fight cancer requires yet another layer of data, leading to a true "n=1" medicine.

One of the challenges with neoepitope discovery and targeting will be the management of Big Data: teraFLOPS of compute resources in a cloud environment are required to generate, manage and analyze terabytes of sequencing data, including whole genome and/or whole exome sequencing, RNA sequencing and molecular modeling of immune presentation of neoepitopes. These activities require compute and storage under HIPAA, as well as high-speed and large-bandwidth connectivity for rapidly transiting sequence data from sequencing labs to supercompute/cloud environments, such that derivation and delivery of neoepitope targeting platforms are enabled in actionable time for each patient. Long term storage of data from multiple biopsies for each patient also needs to be provided. These challenges require significant infrastructure and resources, which are already realized by some private, Big Data supercompute clouds interconnected by dedicated fiber infrastructure capable of transporting terabytes of data at terabits per second. Such infrastructures had originally been developed for financial trading markets, but are now retrofitted to meet the needs of sequencing analysis and neoepitope discovery.

## I. Outlook

Realizing personalized medicine for every patient around the world would result in Big Data challenges of unprecedented scale. Large investments in computing and storage facilities are required and all stakeholders, including patients, doctors, nurses, insurers, lawmakers and the public, need to get involved, educated and trained. Privacy and safety concerns need to be addressed and the general public needs to understand the eventual benefits of a personalized medicine involving Big Data technologies and patient profiling.

Many efforts are underway to strengthen the role of personalized medicine. Among them is President Obama's "Precision Medicine Initiative" (PMI) [141].

# VIII. ASSESSMENTS AND CONCLUSIONS

It is unquestionable that healthcare will experience dramatic changes in the coming years and that digitalization and largescale data analytics will be among the key technologies. Precision healthcare —with enormous potential for a better, more effective, and personalized treatment of cancer and other diseases— will require the acquisition, exchange, storage and analysis of huge amounts of data generated in research and clinical practice. Molecular patient data will bring new richness to patient profiles, including genome profiles and expression profiles. The EHR has the potential to become the central digital fingerprint of a patient and it will be the basis for optimal personalized treatment decisions. It will provide valuable information for a learning healthcare system. Completeness and accuracy of information is a precondition that interventional causal conclusions can be derived. A tight and timely integration of EHR information, i.e. real-world data, will ensure that newest findings can immediately be transported into clinical practice. With readily available population data and well-defined outcome measures, the effectiveness of a new treatment or a new drug can be evaluated rapidly and caregivers can be advised to adapt accordingly.

High volumes of data will be generated by continuous healthcare which will permit the monitoring of patients with chronic problems and will generate data streams to be managed and analyzed in real time, enabling continuous screening and early intervention. Trusted data centers might become an individual's health memory and support the management of the health of individuals and their families. They will enable functionalities such as reminders, alarming, health advice and the initiation of preventive measures.

Despite clear benefits, it is still largely unclear how exactly and when exactly the impact will be realized. There is a lot of excitement and activity in continuous healthcare and personalized medicine but, in general, we are currently still far from generally accepted solutions. Data privacy, liability and other legal concerns, as well as viable data-driven business models, are unsolved issues. Despite these uncertainties, we already see a lot of public and private investments.

A challenging question is how an intelligent learning health-care system should interact with the individual to achieve engagement and provide best user experience. When and how should such a system interfere with the individual's life? Should the individual be informed on a likely positive finding? A commonly discussed example is Huntington's disease for which genetic tests exist but currently no cure. Less dramatic but still potentially bothersome are health concerns such as overweight: How often should an individual be reminded that weight loss and exercise would increase longevity? What is just the right level of decision support and interference in an individual's life? Maybe be an individual does not want to know about a condition or a problem? Maybe the individual does not want anybody to know? Patient engagement and user experience is increasingly getting in focus.<sup>35</sup>

There is also the question in which way a learning healthcare system should support treatment decisions. Supplying newest research results on a patient's problems might obviously be a good idea, but it is largely an open question how decision support can be integrated into the workflow of the caregivers. Can a caregiver accept results from a machine learning system

<sup>35</sup> https://www.dartmouth-hitchcock.org/stories/article/40037

that uses high dimensional patient information but where it is difficult or impossible to explain the reasoning behind its predictions and recommendations?

In this paper we have described the state of the healthcare systems and various attempts to improve it via more effective processes, standardized data formats, data exchange in trusted networks, and improvements in policies and reimbursement rules. It is important that all involved stake holders, but in particular caregivers and patients, personally experience the benefits of the new developments and not just suffer from the additional bureaucratic burden of, for example, reporting and maintaining a high-quality EHR: Trust must be generated and benefits must readily be apparent since the vision of a better and more efficient future healthcare only works with support from all groups.

Greatest concerns are clearly associated with data privacy and data security and generally acceptable solutions are not yet available. The Genetic Information Non-Discrimination Act in the U.S. is partially addressing data protection for genetic information. In general, one might want to distinguish between the privacy concerns of patients with severe health issues, who might see clearer benefits from sharing their data, and individuals without major health problems, who might not see immediate benefits in data sharing. Privacy protection is a very serious issue: Imagine a hack which gives access to your complete (in the future more rich and meaningful) health record to un-authorized parties, which would open the door to discrimination and black mail!

Currently, sustainable data-driven business models are still unclear and new reimbursement models must be developed that are tailored towards a data-driven medicine. The legal situation of what is allowed and what is not allowed must be clear and unambiguous, which is not the case in many countries: Viable business models require a solid legal basis.

Notwithstanding the indicated challenges: we hope that we could convey in this paper the great potential of digitalization and large scale data analytics for a better and more effective patient care.

# ACKNOWLEDGMENT

Volker Tresp acknowledges support by the German Federal Ministry for Economic Affairs and Energy, technology program "Smart Data" (grant 01MT14001).

#### REFERENCES

- S. Biesdorf and F. Niedermann, "Healthcare's digital future," McKinsey & Company, 2014.
- [2] J. Manyika, M. Chui, B. Brown, J. Bughin, R. Dobbs, C. Roxburgh, and A. H. Byers, "Big data: The next frontier for innovation, competition, and productivity," *McKinsey Global Institute*, 2011.
- [3] K. Conger, "Data deluge: mastering medicine's tidal wave, chapter B!g data. what it means for our health and the future of medical research," 2012.
- [4] B. Kayyali, D. Knott, and S. Van Kuiken, "The big-data revolution in US health care: Accelerating value and innovation," Mc Kinsey & Company, 2013.
- [5] Wikipedia, "Health information exchange Wikipedia, the free encyclopedia," 2016. [Online]. Available: https://en.wikipedia.org/wiki/ Health-information-exchange

- [6] National Academies of Sciences, Engineering, and Medicine, "The learning health care system in America," 2012. [Online]. Available: http://www.nationalacademies.org/hmd/Activities/Quality/ LearningHealthCare.aspx
- [7] A. Rind, T. D. Wang, W. Aigner, S. Miksch, K. Wongsuphasawat, C. Plaisant, and B. Shneiderman, "Interactive information visualization to explore and query electronic health records," *Foundations and Trends in Human-Computer Interaction*, vol. 5, no. 3, pp. 207–298, 2011.
- [8] M. A. Musen, B. Middleton, and R. A. Greenes, "Clinical decisionsupport systems," in *Biomedical informatics*. Springer, 2014, pp. 643–674.
- [9] T. J. Bright, A. Wong, R. Dhurjati, E. Bristow, L. Bastian, R. R. Coeytaux, G. Samsa, V. Hasselblad, J. W. Williams, M. D. Musty et al., "Effect of clinical decision-support systems: a systematic review," *Annals of internal medicine*, vol. 157, no. 1, pp. 29–43, 2012.
- [10] J. Bresnick, "Healthcare big data analytics: From description to prescription," *Healthcare IT Analytics*, 2015.
- [11] S. Blumenthal and G. Somashekar, "Advancing health with information technology in the 21st century," *Huffpost Healthy Living*, 2015.
- [12] SAS, "Applying data to improve patient-centric and personalized medicine," SAS white paper, 2015.
- [13] W. R. Hersh, "Information retrieval for healthcare," in *Healthcare Data Analytics*., 2015, pp. 467–505. [Online]. Available: http://www.crcnetbase.com/doi/abs/10.1201/b18588-17
- [14] R. Rahman and C. K. Reddy, "Electronic health records: A survey," in *Healthcare Data Analytics.*, 2015, pp. 21–59. [Online]. Available: http://www.crcnetbase.com/doi/abs/10.1201/b18588-4
- [15] D. Blumenthal, "Launching HIteCH," New England Journal of Medicine, vol. 362, no. 5, pp. 382–385, 2010.
- [16] D. Charles, M. Gabriel, and M. Furukawa, "Adoption of electronic health record systems among us non-federal acute care hospitals: 2008-2013. 2014." 2014.
- [17] C.-J. Hsiao, E. Hing et al., Use and Characteristics of Electronic Health Record Systems Among Office-Based Physician Practices, United States, 2001-2013. US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics, 2014.
- [18] J. McCarthy, "Doctors like EHRs even less than they did five years ago," *Healthcare IT News*, 2015.
- [19] E. Snell, "Top 10 healthcare data breaches of 2015," 2015. [Online]. Available: http://healthitsecurity.com/news/ top-10-healthcare-data-breaches-of-2015
- [20] N. Clynch and J. Kellett, "Medical documentation: Part of the solution, or part of the problem? A narrative review of the literature on the time spent on and value of medical documentation," *International journal of medical informatics*, vol. 84, no. 4, pp. 221–228, 2015.
- [21] M. W. Friedberg, P. G. Chen, F. M. Aunon, K. R. Van Busum, C. Pham, J. P. Caloyeras, S. Mattke, E. Pitchforth, D. D. Quigley, R. H. Brook et al., Factors affecting physician professional satisfaction and their implications for patient care, health systems, and health policy. Rand Corporation, 2013.
- [22] C. J. McDonald, F. M. Callaghan, A. Weissman, R. M. Goodwin, M. Mundkur, and T. Kuhn, "Use of internist's free time by ambulatory care electronic medical record systems," *JAMA internal medicine*, vol. 174, no. 11, pp. 1860–1863, 2014.
- [23] C. J. McDonald and M. H. McDonald, "Invited commentary electronic medical records and preserving primary care physicians' time," Archives of internal medicine, vol. 172, no. 3, pp. 285–287, 2012.
- [24] V. Mihalef, R. I. Ionasec, P. Sharma, B. Georgescu, I. Voigt, M. Suehling, and D. Comaniciu, "Patient-specific modelling of whole heart anatomy, dynamics and haemodynamics from four-dimensional cardiac CT images," *Interface Focus*, vol. 1, no. 3, pp. 286–296, 2011.
- [25] D. R. Padfield, P. R. S. Mendonça, and S. Gupta, "Biomedical image

- analysis," in *Healthcare Data Analytics.*, 2015, pp. 61–89. [Online]. Available: http://www.crcnetbase.com/doi/abs/10.1201/b18588-5
- [26] S. Liao, S. Yu, M. Wolf, G. Hermosillo, Y. Zhan, Y. Shinagawa, Z. Peng, X. S. Zhou, L. Bogoni, and M. Salganicoff, "Computer-assisted medical image analysis systems," in *Healthcare Data Analytics.*, 2015, pp. 657–683. [Online]. Available: http://www.crcnetbase.com/doi/abs/10.1201/b18588-24
- [27] J. Novet, "Deep learning startup Enlitic raises \$10m from radiology company Capitol Health," venturebeat, 2015.
- [28] V. Tresp, S. Zillner, M. J. Costa, Y. Huang, A. Cavallaro, P. A. Fasching, A. Reis, M. Sedlmayr, T. Ganslandt, K. Budde et al., "Towards a new science of a clinical data intelligence," arXiv preprint arXiv:1311.4180, 2013.
- [29] K. Raja and S. Jonnalagadda, "Natural language processing and data mining for clinical text," in *Healthcare Data Analytics.*, 2015, pp. 219–249. [Online]. Available: http://www.crcnetbase.com/doi/abs/10. 1201/b18588-9
- [30] C. J. McDonald, J. M. Overhage, P. R. Dexter, L. Blevins, J. Meeks-Johnson, J. G. Suico, M. C. Tucker, and G. Schadow, "Canopy computing: using the web in clinical practice," *Jama*, vol. 280, no. 15, pp. 1325–1329, 1998.
- [31] J. Bresnick, "How can healthcare big data analytics bust data silos?" Healthcare IT News, 2015.
- [32] S. N. Murphy, G. Weber, M. Mendis, V. Gainer, H. C. Chueh, S. Churchill, and I. Kohane, "Serving the enterprise and beyond with informatics for integrating biology and the bedside (i2b2)," *Journal* of the American Medical Informatics Association, vol. 17, no. 2, pp. 124–130, 2010.
- [33] B. D. Athey, M. Braxenthaler, M. Haas, and Y. Guo, "tranSMART: an open source and community-driven informatics and data sharing platform for clinical and translational research," AMIA Summits on Translational Science Proceedings, vol. 2013, p. 6, 2013.
- [34] Y. Park and J. Ghosh, "Privacy-preserving data publishing methods in healthcare," in *Healthcare Data Analytics*., 2015, pp. 507–529. [Online]. Available: http://www.crcnetbase.com/doi/abs/10.1201/b18588-18
- [35] G. Danezis, J. Domingo-Ferrer, M. Hansen, J.-H. Hoepman, D. L. Metayer, R. Tirtea, and S. Schiffner, "Privacy and data protection by design-from policy to engineering," arXiv preprint arXiv:1501.03726, 2015.
- [36] D. Raths, "UPMC funds pittsburgh health data alliance," Health Affairs, 2015
- [37] B. Spice, "The future of health care is in the data," 2015. [Online]. Available: https://www.cs.cmu.edu/news/future-health-care-data
- [38] W. Flanagan, "UIUC and the Mayo Clinic get \$9.3 million to try and solve the biomed big data puzzle," *chicagoinno*, 2014.
- [39] C. Marcum, "The rise of big data in health care," 2014. [Online]. Available: http://www.kpihp.org/ how-big-data-can-inform-healthcare-decisions/#sthash.UbfR4h4s. dpbs
- [40] J. Byron, "Big data improves care for Kaiser Permanente's smallest members," Kaiser Permanente Division of Research, 2014.
- [41] J. M. Overhage, P. B. Ryan, M. J. Schuemie, and P. E. Stang, "Desideratum for evidence based epidemiology," *Drug safety*, vol. 36, no. 1, pp. 5–14, 2013.
- [42] G. Hripcsak, J. Duke, N. Shah, C. Reich, V. Huser, M. Schuemie, M. Suchard, R. Park, I. Wong, P. Rijnbeek et al., "Observational health data sciences and informatics (OHDSI): opportunities for observational researchers," MEDINFO, vol. 15, 2015.
- [43] D. Sonntag, V. Tresp, S. Zillner, A. Cavallaro, M. Hammon, A. Reis, P. A. Fasching, M. Sedlmayr, T. Ganslandt, H.-U. Prokosch et al., "The clinical data intelligence project," *Informatik-Spektrum*, pp. 1–11, 2015
- [44] C. Esteban, D. Schmidt, D. Krompass, and V. Tresp, "Predicting sequences of clinical events by using a personalized temporal latent

- embedding model," *IEEE International Conference on Healthcare Informatics (ICHI)*, 2015.
- [45] J. Novet, "Google's deepmind ai group unveils health care ambitions," 2016. [Online]. Available: http://venturebeat.com/2016/02/ 24/googles-deepmind-ai-group-unveils-heath-care-ambitions/
- [46] C. Esteban, O. Staeck, Y. Yang, and V. Tresp, "Predicting clinical events by combining static and dynamic information using recurrent neural networks," *Proceedings of the IEEE International Conference* on Healthcare Informatics (ICHI), 2016.
- [47] Harvard Business Review, "How big data impacts healthcare," 2014. [Online]. Available: https://hbr.org/resources/pdfs/comm/sap/ 18826-HBR-SAP-Healthcare-Aug-2014.pdf
- [48] I. M. Tomek, A. L. Sabel, M. I. Froimson, G. Muschler, D. S. Jevsevar, K. M. Koenig, D. G. Lewallen, J. M. Naessens, L. A. Savitz, J. L. Westrich et al., "A collaborative of leading health systems finds wide variations in total knee replacement delivery and takes steps to improve value," *Health Affairs*, pp. 10–1377, 2012.
- [49] D. Lampe, "U-M launching \$100 million data science initiative," 2015. [Online]. Available: https://record.umich.edu/articles/ u-m-launching-100-million-data-science-initiative
- [50] D. Naegele, "Analytics tool predicts readmission with 82% accuracy," 2015. [Online]. Available: http://www.infieldhealth.com/ blog/analytics-tool-predicts-readmission-with-82-accuracy
- [51] Penn Medicine, "Penn research team receives \$5 million grant to use big data to improve health," 2016. [Online]. Available: http://www.uphs.upenn.edu/news/News-Releases/2016/02/polsky/
- [52] J. Bresnick, "Precision medicine, big data analytics intersect for better care," *Healthcare IT Analytics*, 2015.
- [53] Forum members, "Stratified, personalised or P4 medicine: a new direction for placing the patient at the centre of healthcare and health education (may 2015) summary of a joint forum meeting held on 12 may 2015," Supported by the Academy of Medical Sciences, the University of Southampton, Science Europe and the Medical Research Council, Tech. Rep., 2015.
- [54] A. D. Harris, J. C. McGregor, E. N. Perencevich, J. P. Furuno, J. Zhu, D. E. Peterson, and J. Finkelstein, "The use and interpretation of quasi-experimental studies in medical informatics," *Journal of the American Medical Informatics Association*, vol. 13, no. 1, pp. 16–23, 2006.
- [55] A. Rubenfire, "Hospitals use big-data platform to improve care," Modern Healthcare, 2015.
- [56] B. E. Huang, W. Mulyasasmita, and G. Rajagopal, "The path from big data to precision medicine," *Expert Review of Precision Medicine and Drug Development*, no. just-accepted, 2016.
- [57] J. Fan, F. Han, and H. Liu, "Challenges of big data analysis," *National science review*, vol. 1, no. 2, pp. 293–314, 2014.
- [58] F. A. Dahl, M. Grotle, J. Š. Benth, and B. Natvig, "Data splitting as a countermeasure against hypothesis fishing: with a case study of predictors for low back pain," *European journal of epidemiology*, vol. 23, no. 4, pp. 237–242, 2008.
- [59] P. C. Tang, M. Ralston, M. F. Arrigotti, L. Qureshi, and J. Graham, "Comparison of methodologies for calculating quality measures based on administrative data versus clinical data from an electronic health record system: implications for performance measures," *Journal of the American Medical Informatics Association*, vol. 14, no. 1, pp. 10–15, 2007
- [60] M. Rosenman, J. He, J. Martin, K. Nutakki, I. Gradus-Pizlo, and S. L. Hui, "Agreement between claims and electronic medical records data for CHF in inpatients," in *Pharmacoepidemiology And Drug Safety*, vol. 22, 2013, pp. 269–269.
- [61] V. Chandola, J. C. Schryver, and S. R. Sukumar, "Fraud detection in healthcare," in *Healthcare Data Analytics*, 2015, pp. 577–598. [Online]. Available: http://www.crcnetbase.com/doi/abs/10.1201/b18588-21
- [62] K. M. Sullivan, "But doctor, I still have both feet! Remedial problems faced by victims of medical identity theft," Am J Law Med., vol. 35, no. 4, pp. 647–81, 2009.

- [63] A. Betz, "The experiences of adult/child identity theft victims," Digital Repository Iowa State University, 2012.
- [64] S. Chapman, "Capturing cancer data in real time," For The Record, 2013.
- [65] B. E. Dixon, A. Zafar, and J. M. Overhage, "A framework for evaluating the costs, effort, and value of nationwide health information exchange," *Journal of the American Medical Informatics Association*, vol. 17, no. 3, pp. 295–301, 2010.
- [66] https://www.healthit.gov/sites/default/files/nationwide-interoperability-roadmap-draft-version-1.0.pdf, "Connecting health and care for the nation: A shared nationwide interoperability roadmap," Office of the National Coordinator for Health Information Technology (ONC), 2015.
- [67] Wikipedia, "Health and social care information centre Wikipedia, the free encyclopedia," 2016. [Online]. Available: https://en.wikipedia. org/wiki/Health-and-Social-Care-Information-Centre
- [68] OECD, "Health at a glance 2015," OECD Publishing, 2015. [Online]. Available: /content/book/health\_glance-2015-en
- [69] A. McKethan and B. P. Center, Improving Quality and Value in the US: Health Care System. Bipartisan Policy Center, 2009.
- [70] R. Bayer and S. Galea, "Public health in the precision-medicine era," New England Journal of Medicine, vol. 373, no. 6, pp. 499–501, 2015.
- [71] J. Bresnick, "Is there conflict between precision medicine, population health?" *Healthcare IT Analytics*, 2015.
- [72] Multiple authors, "HIPAA compliant hosting," OnLINE TECH, 2015.
- [73] M. E. Tucker, "Doctors, not just patients, use Wikipedia, too: IMS report," Medscape Medical News, 2014.
- [74] K. Christensen, "The quest for the Amazon of healthcare," Forbes India, Tech. Rep., 2016. [Online]. Available: http://forbesindia.com/ article/rotman/the-quest-for-the-amazon-of-healthcare
- [75] A. Kotov, "Social media analytics for healthcare," in *Healthcare Data Analytics*., 2015, pp. 309–340. [Online]. Available: http://www.crcnetbase.com/doi/abs/10.1201/b18588-11
- [76] E. Horvitz and D. Mulligan, "Data, privacy, and the greater good," Science, vol. 349, no. 6245, pp. 253–255, 2015.
- [77] D. Lazer, R. Kennedy, G. King, and A. Vespignani, "The parable of Google flu: traps in big data analysis," *Science*, vol. 343, no. 14 March, 2014
- [78] D. R. Olson, K. J. Konty, M. Paladini, C. Viboud, and L. Simonsen, "Reassessing Google flu trends data for detection of seasonal and pandemic influenza: a comparative epidemiological study at three geographic scales," *PLoS Comput Biol*, vol. 9, no. 10, p. e1003256, 2013.
- [79] A. C. J. Janssens and P. Kraft, "Research conducted using data obtained through online communities: ethical implications of methodological limitations," *PLOS*, 2012.
- [80] R. Kalf, R. Bakker, and C. Janssens, "Predictive ability of direct-to-consumer pharmacogenetic testing: when is lack of evidence really lack of evidence?" *Pharmacogenomics*, vol. 14, no. 4, pp. 341–344, 2013
- [81] J. Wilkinson, "How companies are secretly tracking employees' health and private lives with 'big data' to save money," *DailyMail*, 2016.
- [82] S. Gupta and J. Riis, "Patientslikeme: An online community of patients," Harvard Business School Marketing Unit Case, no. 511-093, 2011.
- [83] C. A. Brownstein, J. S. Brownstein, D. S. Williams, P. Wicks, and J. A. Heywood, "The power of social networking in medicine," *Nature biotechnology*, vol. 27, no. 10, pp. 888–890, 2009.
- [84] J. H. Frost and M. P. Massagli, "Social uses of personal health information within patientslikeme, an online patient community: what can happen when patients have access to one another's data," *Journal* of Medical Internet Research, vol. 10, no. 3, 2008.
- [85] P. Wicks, M. Massagli, J. Frost, C. Brownstein, S. Okun, T. Vaughan, R. Bradley, and J. Heywood, "Sharing health data for better outcomes on patientslikeme," *Journal of medical Internet research*, vol. 12, no. 2, 2010.

- [86] A. Sunyaev, D. Chornyi, C. Mauro, and H. Krcmar, "Evaluation framework for personal health records: Microsoft HealthVault vs. Google health," in *System Sciences (HICSS)*, 2010 43rd Hawaii International Conference on. IEEE, 2010, pp. 1–10.
- [87] F. Collins, "How to fulfill the true promise of "mhealth"," Scientific American, vol. 307, no. 1, pp. 16–16, 2012.
- [88] M. Kay, J. Santos, and M. Takane, "mhealth: New horizons for health through mobile technologies," World Health Organization, pp. 66–71, 2011
- [89] S. Fox and M. Duggan, "Main findings: Mobile health," 2016. [Online]. Available: http://www.pewinternet.org/2012/11/08/main-findings-6/
- [90] M.-P. Gagnon, P. Ngangue, J. Payne-Gagnon, and M. Desmartis, "m-health adoption by healthcare professionals: a systematic review," *Journal of the American Medical Informatics Association*, vol. 23, no. 1, pp. 212–220, 2016.
- [91] C. Free, G. Phillips, L. Watson, L. Galli, L. Felix, P. Edwards, V. Patel, and A. Haines, "The effectiveness of mobile-health technologies to improve health care service delivery processes: a systematic review and meta-analysis," *PLoS Med*, vol. 10, no. 1, p. e1001363, 2013.
- [92] C. B. Aranda-Jan, N. Mohutsiwa-Dibe, and S. Loukanova, "Systematic review on what works, what does not work and why of implementation of mobile health (mhealth) projects in Africa," *BMC public health*, vol. 14, no. 1, p. 188, 2014.
- [93] S. W. Miyamoto, S. Henderson, H. M. Young, A. Pande, and J. J. Han, "Tracking health data is not enough: A qualitative exploration of the role of healthcare partnerships and mhealth technology to promote physical activity and to sustain behavior change," *JMIR mHealth and uHealth*, vol. 4, no. 1, p. e5, 2016.
- [94] E. Jovanov and A. Milenkovic, "Body area networks for ubiquitous healthcare applications: opportunities and challenges," *Journal of medical systems*, vol. 35, no. 5, pp. 1245–1254, 2011.
- [95] T. Laksanasopin, T. W. Guo, S. Nayak, A. A. Sridhara, S. Xie, O. O. Olowookere, P. Cadinu, F. Meng, N. H. Chee, J. Kim et al., "A smartphone dongle for diagnosis of infectious diseases at the point of care," *Science translational medicine*, vol. 7, no. 273, pp. 273re1–273re1, 2015.
- [96] S. Knowlton, I. Sencan, Y. Aytar, J. Khoory, M. Heeney, I. Ghiran, and S. Tasoglu, "Sickle cell detection using a smartphone," *Scientific reports*, vol. 5, 2015.
- [97] L. E. Burke, J. Ma, K. M. Azar, G. G. Bennett, E. D. Peterson, Y. Zheng, W. Riley, J. Stephens, S. H. Shah, B. Suffoletto *et al.*, "Current science on consumer use of mobile health for cardiovascular disease prevention a scientific statement from the american heart association," *Circulation*, vol. 132, no. 12, pp. 1157–1213, 2015.
- [98] S. Hamine, E. Gerth-Guyette, D. Faulx, B. B. Green, and A. S. Ginsburg, "Impact of mhealth chronic disease management on treatment adherence and patient outcomes: a systematic review," *Journal of medical Internet research*, vol. 17, no. 2, 2015.
- [99] N. Crotti, "How the Apple watch can collect patient data," EE Times, 2015.
- [100] M. Herper, "Can Apple and IBM change health care? Five big questions," Forbes, 2015.
- [101] M. Swan, "The quantified self: Fundamental disruption in big data science and biological discovery," *Big Data*, vol. 1, no. 2, pp. 85–99, 2013.
- [102] H. Caouette, "Harris poll survey finds patients want a deeper digital connection with their doctors," 2015. [Online]. Available: https: //www.eclinicalworks.com/pr-harris-poll-patient-engagement-survey/
- [103] M. B. Hamel, N. G. Cortez, I. G. Cohen, and A. S. Kesselheim, "FDA regulation of mobile health technologies," *New England Journal of Medicine*, vol. 371, no. 4, pp. 372–379, 2014.
- [104] S. Ogino, P. Lochhead, A. T. Chan, R. Nishihara, E. Cho, B. M. Wolpin, J. A. Meyerhardt, A. Meissner, E. S. Schernhammer, C. S. Fuchs *et al.*, "Molecular pathological epidemiology of epigenetics:

- emerging integrative science to analyze environment, host, and disease," *Modern Pathology*, vol. 26, no. 4, pp. 465–484, 2013.
- [105] E. S. Lander, L. M. Linton, B. Birren, C. Nusbaum, M. C. Zody, J. Baldwin, K. Devon, K. Dewar, M. Doyle, W. FitzHugh *et al.*, "Initial sequencing and analysis of the human genome," *Nature*, vol. 409, no. 6822, pp. 860–921, 2001.
- [106] J. C. Venter, M. D. Adams, E. W. Myers, P. W. Li, R. J. Mural, G. G. Sutton, H. O. Smith, M. Yandell, C. A. Evans, R. A. Holt *et al.*, "The sequence of the human genome," *Science*, vol. 291, no. 5507, pp. 1304–1351, 2001.
- [107] S. Kulkarni and P. Ma, "Personalized medicine: The path forward," McKinsey & Company, vol. 3, pp. 1–48, 2013.
- [108] E. Duncan, M. Brown, and E. M. Shore, "The revolution in human monogenic disease mapping," *Genes*, vol. 5, no. 3, pp. 792–803, 2014.
- [109] P. Anand, A. B. Kunnumakara, C. Sundaram, K. B. Harikumar, S. T. Tharakan, O. S. Lai, B. Sung, and B. B. Aggarwal, "Cancer is a preventable disease that requires major lifestyle changes," *Pharmaceutical research*, vol. 25, no. 9, pp. 2097–2116, 2008.
- [110] P. M. Visscher, M. A. Brown, M. I. McCarthy, and J. Yang, "Five years of GWAS discovery," *The American Journal of Human Genetics*, vol. 90, no. 1, pp. 7–24, 2012.
- [111] Cancer Genome Atlas Network and others, "Comprehensive molecular portraits of human breast tumours," *Nature*, vol. 490, no. 7418, pp. 61–70, 2012.
- [112] C. Bettegowda, M. Sausen, R. J. Leary, I. Kinde, Y. Wang, N. Agrawal, B. R. Bartlett, H. Wang, B. Luber, R. M. Alani et al., "Detection of circulating tumor DNA in early-and late-stage human malignancies," Science translational medicine, vol. 6, no. 224, pp. 224ra24–224ra24, 2014.
- [113] J. R. Nevins and A. Potti, "Mining gene expression profiles: expression signatures as cancer phenotypes," *Nature Reviews Genetics*, vol. 8, no. 8, pp. 601–609, 2007.
- [114] D. V. Catenacci, W.-L. Liao, L. Zhao, E. Whitcomb, L. Henderson, E. O'Day, P. Xu, S. Thyparambil, D. Krizman, K. Bengali et al., "Massspectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: comparison to IHC and FISH," Gastric Cancer, pp. 1–14, 2015.
- [115] I. F. Tannock and J. A. Hickman, "Limits to personalized cancer medicine," New England Journal of Medicine, vol. 375, 2016.
- [116] Y. Miki, J. Swensen, D. Shattuck-Eidens, P. A. Futreal, K. Harshman, S. Tavtigian, Q. Liu, C. Cochran, L. M. Bennett, W. Ding *et al.*, "A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1," *Science*, vol. 266, no. 5182, pp. 66–71, 1994.
- [117] R. Wooster, G. Bignell, J. Lancaster, S. Swift, S. Seal, J. Mangion, N. Collins, S. Gregory, C. Gumbs, G. Micklem *et al.*, "Identification of the breast cancer susceptibility gene BRCA2," *Nature*, vol. 378, no. 6559, pp. 789–792, 1995.
- [118] D. J. Slamon, G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich, and W. L. McGuire, "Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene," *Science*, vol. 235, no. 4785, pp. 177–182, 1987.
- [119] B. B. Spear, M. Heath-Chiozzi, and J. Huff, "Clinical application of pharmacogenetics," *Trends in molecular medicine*, vol. 7, no. 5, pp. 201–204, 2001.
- [120] M. Rastegar-Mojarad and R. Prasad, "Toward a complete database of drug repurposing candidates extracted from social media, biomedical literature, and genetic data," in *Healthcare Informatics (ICHI)*, 2015 International Conference on. IEEE, 2015, pp. 494–494.
- [121] A. Aliper, S. Plis, A. Artemov, A. Ulloa, P. Mamoshina, and A. Zhavoronkov, "Deep learning applications for predicting pharmacological properties of drugs and drug repurposing using transcriptomic data," *Molecular pharmaceutics*, 2016.
- [122] D. M. Hyman, I. Puzanov, V. Subbiah, J. E. Faris, I. Chau, J.-Y. Blay, J. Wolf, N. S. Raje, E. L. Diamond, A. Hollebecque *et al.*, "Vemurafenib in multiple nonmelanoma cancers with braf v600 mutations," *New England Journal of Medicine*, vol. 373, no. 8, pp. 726–736, 2015.

- [123] E. D. Green, M. S. Guyer, N. H. G. R. Institute et al., "Charting a course for genomic medicine from base pairs to bedside," *Nature*, vol. 470, no. 7333, pp. 204–213, 2011.
- [124] J. L. Fackler and A. L. McGuire, "Paving the way to personalized genomic medicine: steps to successful implementation," *Current pharmacogenomics and personalized medicine*, vol. 7, no. 2, p. 125, 2009.
- [125] K. Michailidou, P. Hall, A. Gonzalez-Neira, M. Ghoussaini, J. Dennis, R. L. Milne, M. K. Schmidt, J. Chang-Claude, S. E. Bojesen, M. K. Bolla *et al.*, "Large-scale genotyping identifies 41 new loci associated with breast cancer risk," *Nature genetics*, vol. 45, no. 4, pp. 353–361, 2013.
- [126] 1000 Genomes Project Consortium and others, "A map of human genome variation from population-scale sequencing," *Nature*, vol. 467, no. 7319, pp. 1061–1073, 2010.
- [127] I. Hirtzlin, C. Dubreuil, N. Préaubert, J. Duchier, B. Jansen, J. Simon, P. L. de Faria, A. Perez-Lezaun, B. Visser, G. D. Williams et al., "An empirical survey on biobanking of human genetic material and data in six EU countries," European Journal of Human Genetics, vol. 11, no. 6, pp. 475–488, 2003.
- [128] P. Soon-Shiong, S. Rabizadeh, S. Benz, F. Cecchi, T. Hembrough, E. Mahen, K. Burton, C. Song, F. Senecal, S. Schmechel et al., "Abstract p6-05-08: Integrating whole exome sequencing data with RNAseq and quantitative proteomics to better inform clinical treatment decisions in patients with metastatic triple negative breast cancer," Cancer Research, vol. 76, no. 4 Supplement, pp. P6-05, 2016.
- [129] C. Hayden, "Genome researchers raise alarm over big data," *Nature News*, 2015.
- [130] Z. D. Stephens, S. Y. Lee, F. Faghri, R. H. Campbell, C. Zhai, M. J. Efron, R. Iyer, M. C. Schatz, S. Sinha, and G. E. Robinson, "Big data: Astronomical or genomical?" *PLoS Biol*, vol. 13, no. 7, p. e1002195, 2015.
- [131] B. H. Shirts, J. S. Salama, S. J. Aronson, W. K. Chung, S. W. Gray, L. A. Hindorff, G. P. Jarvik, S. E. Plon, E. M. Stoffel, P. Z. Tarczy-Hornoch et al., "CSER and eMERGE: current and potential state of the display of genetic information in the electronic health record," *Journal* of the American Medical Informatics Association, p. ocv065, 2015.
- [132] A. Shah, A. K. Stewart, A. Kolacevski, D. Michels, and R. Miller, "Building a rapid learning health care system for oncology: Why CancerLinQ collects identifiable health information to achieve its vision," *Journal of Clinical Oncology*, p. JCO650598, 2016.
- [133] A. Abernethy, "ASCO's CancerLinQ and breast cancer outcomes," in European Journal Of Cancer, vol. 49. Elsevier Sci Ltd The Boulevard, Langford Lane, Kidlington, Oxford Ox5 1Gb, Oxon, England, 2013, pp. S37–S37.
- [134] M. Ratner, "IBM's Watson group signs up genomics partners," *Nature biotechnology*, vol. 33, no. 1, pp. 10–11, 2015.
- [135] Tech Savvy, "Watson will see you now: a supercomputer to help clinicians make informed treatment decisions," 2015.
- [136] Ö. Türeci, M. Vormehr, M. Diken, S. Kreiter, C. Huber, and U. Sahin, "Targeting the heterogeneity of cancer with individualized neoepitope vaccines," *Clinical Cancer Research*, vol. 22, no. 8, pp. 1885–1896, 2016.
- [137] P. K. Srivastava, "Neoepitopes of cancers: Looking back, looking ahead," Cancer immunology research, vol. 3, no. 9, pp. 969–977, 2015.
- [138] S. Jones, V. Anagnostou, K. Lytle, S. Parpart-Li, M. Nesselbush, D. R. Riley, M. Shukla, B. Chesnick, M. Kadan, E. Papp et al., "Personalized genomic analyses for cancer mutation discovery and interpretation," Science translational medicine, vol. 7, no. 283, pp. 283ra53–283ra53, 2015
- [139] M. A. Morse, A. Chaudhry, E. S. Gabitzsch, A. C. Hobeika, T. Osada, T. M. Clay, A. Amalfitano, B. K. Burnett, G. R. Devi, D. S. Hsu et al., "Novel adenoviral vector induces T-cell responses despite antiadenoviral neutralizing antibodies in colorectal cancer patients," Cancer Immunology, Immunotherapy, vol. 62, no. 8, pp. 1293–1301, 2013.

- [140] J. P. Balint, E. S. Gabitzsch, A. Rice, Y. Latchman, Y. Xu, G. L. Messerschmidt, A. Chaudhry, M. A. Morse, and F. R. Jones, "Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA (6D) vaccine in late-stage colorectal cancer," Cancer Immunology, Immunotherapy, vol. 64, no. 8, pp. 977–987, 2015.
- [141] F. S. Collins and H. Varmus, "A new initiative on precision medicine," New England Journal of Medicine, vol. 372, no. 9, pp. 793–795, 2015.